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ABSTRACT 
 
Background 
Wilson Disease (WD)  is an autosomal recessive inherited disorder, which if 
left untreated can be lethal. Its development is due to abnormal copper (Cu) 
metabolism. In particular, reduced copper excretion causes an excessive 
deposition of the ion in many organs such as the liver, central nervous 
system, cornea, kidney, and cardiac muscle, thereby damaging the 
physiological functions of the affected organs. Mutations in the P-type 
adenosine triphosphatase (ATP7B), the gene encoding the copper transporting 
P-type ATPase, are responsible for hepatic copper accumulation. Cu overload 
in the liver produces toxic effects via modulating several molecular 
pathways. 
The recessive ATP7B-H1069Q mutation alone is the most frequent cause of 
WD among Caucasians (~60%). Physiologically, ATP7B transfers copper 
across the membrane into the lumen of the trans-Golgi network (TGN). In 
the Golgi, the metal is incorporated into the serum protein ceruloplasmin 
(CP). In the presence of excessive cytosolic Cu, the metal is localized by 
ATP7B to post-Golgi vesicles and plasma membrane (PM), where it is 
removed via bile canaliculi.  
Overexpression studies in heterologous cell systems show that H1069Q 
mutation results in aberrant protein products that are strongly mis-targeted 
from the TGN towards the endoplasmic reticulum (ER). Despite that, this 
mutant still exhibits residual Cu translocating activity, which might be 
sufficient enough to ward off the disease if the protein is correctly localized 
to the TGN. In this context, our previous work has demonstrated that the 
cytosolic holdase αB-crystallin (CRYAB or Hsp-B5) rescues the proper 
folding, localization and response to Cu overload of ATP7B-H1069Q in Hep-
G2 and COS-7 cells. 
 
Rationale 
Evidence that residual Cu transport activity is retained by ATP7B-H1069Q 
and that correcting agents can indeed localize this mutant to the Golgi 
complex has spurred our great interest in investigating the potentially 
therapeutic implications of these findings. 
My PhD thesis describes the properties of a CRYAB-derived mini-chaperone 
in heterologous or hepatoma-derived cell lines overexpressing ATP7B-
H1069Q and the generation of an isogenic cell model based on induced 
pluripotent stem cells (iPSCs) created from skin fibroblasts of a homozygous 
WD patient and his mother, used  as control, followed by differentiation into 
hepatocyte-like cells (HLCs). 
Main results 
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We found that the CRYAB peptide enters the cytosol and only a small 
fraction is associated with lysosome structures. The peptide interacts with 
ATP7B-H1069Q, rescuing its Golgi localization and trafficking response to 
increased Cu level. 
Other important results, obtained by virtue of our new WD cell model are the 
following: 1) the expression level of the mutant protein in HLCs was only 
30% compared to the control, although ATP7B mRNA levels were similar; 
2) a significant amount of ATP7B-H1069Q (about 35%) reached the Golgi 
complex and was able to redistribute to the endo/lysosomal compartment in 
the presence of Cu excess; 3) most of the newly synthesized mutant 
underwent rapid ER-associated degradation. 
 
Conclusion 
Biochemical optimization of the CRYAB peptide could provide helpful 
insights into its mechanism of action and its potential use for WD treatment. 
Meanwhile, the new isogenic WD cell model is a powerful system to validate 
in vitro results, obtained in heterologous or hepatoma-derived cell lines. In 
this context, ATP7B-H1069Q dysfunction could be tackled by treatments that 
reduce ER-associated degradation, thereby increasing the number of 
molecules reaching the TGN. 
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Abbreviations: 
 
albumin, ALB 
cerulopasmin, CP 
co-immnunoprecipitation, co-IP 
copper, Cu 
C-terminal extension, CTE 
endoplasmic reticulum, ER 
fluorescence energy transfer, FRET 
fluorescence lifetime imaging microscopy, FLIM 
hepatocyte-like cells, HLCs 
induced pluripotent stem cells, iPSCs 
late endosome, LE 
Menkes disease, MD 
N-terminal domain, NTD 
nucleotide binding domain, NBD 
plasma membrane, PM 
quantitative real-time RT-PCR, qPCR 
selected ion monitoring mass spectrometry, SIM-MS 
tetramethylrhodamine, TAMRA 
trans-Golgi network, TGN 
Wilson disease, WD 
1-antitrypsin, AAT 
B-crystallin, CRYAB 
-crystallin domain, CD 
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1. INTRODUCTION 
 
1.1 Copper fate in human metabolism 
  
The human body comprises a sophisticated and delicate homeostatic balance 
of trace elements indispensable for the preservation of all cellular processes. 
Therefore, excessive accumulation or deficiency of these elements must be 
prevented.  
Copper is an emblematic example of such trace elements. It is a cofactor of 
key metabolic enzymes that are involved in antioxidant defence, 
mitochondrial respiration, neurotransmitter synthesis, connective tissue 
formation, pigmentation, peptide amidation, iron metabolism and many other 
physiological pathways (Table1) (1, 2). 
The average daily intake of copper is between 1 and 3 mg, an amount 
adequate for body needs. Although it is well know that the majority of Cu 
adsorption takes place in the duodenum, the molecular mechanisms of dietary 
copper assimilation remain quite elusive. So far, studies have shown that Cu 
enters enterocytes mainly through the high-affinity copper transporter Ctr1 
even though other pathways/transporters might also be involved. Once inside 
the enterocytes, it is exported into the blood by Cu-ATPase ATP7A (Fig. 1) 
(2). Here, the majority of copper is delivered to the liver (3), and to a lesser 
extent to the kidney and other tissues (4). The liver is indeed the central 
organ of copper homeostasis and is primarily responsible for the export of 
excess copper out of the body (2). 
In contrast to the low regulation of Cu uptake into the liver, the export 
mechanism from this organ is a highly regulated copper-dependent process, 
which is mediated by copper-transporting ATPase ATP7B. It is from the 
hepatocytes that copper is distributed to various intracellular destinations 
(Fig. 2).  
The first destinations is the cytosol. Here, it is utilized by a radical-
detoxifying enzyme copper, zinc-dependent superoxide dismutase (SOD1), 
which acquires copper with the help of a specific metallochaperone, viz, the 
copper chaperone of superoxide dismutase (CCS) (5). Then it enters the 
mitochondria. Here, it is incorporated into cytocrome-c oxidase (COX) (6, 7, 
8). Lastly, it reaches its major destination: the trans-Golgi network (TGN). 
This secretory pathway contains Cu-ATPases (ATP7B in hepatocyte), which 
receive the metal from the cytosolic copper transporter Atox1 (9, 10, 11) and 
transfer it across the membrane into the lumen of the TGN. In hepatocytes, it 
is incorporated into the copper-dependent ferroxidase cerulopasmin (CP). CP 
is subsequently secreted into the blood, therefore making this protein the 
major copper containing protein in blood serum (Fig. 1). In addition to CP, 
ATP7B is also required for the elimination of excess copper. This protein 
                                                                                                                           1. Introduction  
 
5 
 
facilitates excess Cu into bile through the relocalization towards the 
LE/lysosomal compartment and the plasma membrane of bile canaliculi (2). 
Therefore, the copper-transporting P-type ATPases exert a key role in 
regulating copper metabolism. Mutations in ATP7A or ATP7B disrupt the 
homeostatic copper balance, causing severe metabolic disorders. 
  
 
 
 
 
 
(P de Bie et al., 2007) 
 
Table 1. Functions of copper-dependent enzymes. 
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(S. Lutsenko et al., 2007) 
 
Fig. 1. Scheme of copper distribution in the human body. 
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(S. Lutsenko et al., 2007) 
 
Fig. 2. Intracellular pathways of copper distribution. Ctr1 transports  Cu 
into the cell. Cox17 may participate in delivery of copper to mitochondrion 
and, together with Sco proteins, facilitates Cu incorporation into COX. CCS 
transfers copper to cytosolic SOD1. The red arrows indicate the pathway in 
which Cu-ATPases are involved. They receive copper from ATOX1, transfer 
it into the lumen of TGN, and export excess copper from the cell.    
 
 
 
1.2 Wilson disease: hallmarks of molecular pathogenesis 
 
Refined mechanisms have evolved to control intake, excretion, and 
cellular distribution of copper. The importance of these regulatory processes 
is underlined by several hereditary human disorders caused by imbalances of 
copper homeostasis. These disorders can broadly be divided into two classes: 
diseases associated with copper deficiency and diseases associated with 
copper excess (1). 
A copper-deficiency disease is Menkes disease (MD). MD is an X-linked 
recessive disorder characterized by a general copper deficiency (12, 13) due 
to mutations or deletions in the gene encoding Cu-ATPase ATP7A (2).  
Its incidence is estimated to range between 1:40000 and 1:350000 (14, 15, 
16). Affected patients display dramatic developmental and neurological 
impairment due to the disrupted delivery of Cu to the brain (17). Moreover, 
they suffer from a variety of other symptoms that are associated with 
decreased function of Cu-dependent enzymes, including connective tissue 
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alterations, lack of pigmentation, and tortuous blood vessels (17, 18, 19). The 
majority of MD patients die in early childhood. 
On the other hand, Wilson disease (WD), also known as hepatolenticular 
degeneration, is an autosomal recessive disorder characterized by defective 
copper excretion  that leads to the deposition of copper and the impairment of 
the normal functions of the affected organs (20). First described by Wilson in 
1912 but not yet clearly characterized, WD has an incidence of 1:7000 live 
births (21). 
Clinical features of WD result from toxic accumulation of copper, primarily 
in the liver and the brain (1). The accumulation in the brain may cause 
Parkinson-like symptoms, including tremor, and dystonia, or 
neuropsychiatric symptoms, such as hypomnesia, and personality 
abnormalities (22, 23). The Kayser-Fleischer (KF) ring, a brown ring around 
the cornea of the eye, is the result of ion accumulation in the cornea. 
Although it is a hallmark of WD, it is not diagnostic for the disease. Copper 
deposition in other organs may cause corresponding clinical disorders: 
osteoarthritis, impaired kidney function, and cardiomyopathy (24). 
Liver is the major organ for copper deposition in patients with WD. Excess 
copper causes a large spectrum of hepatic dysfunctions ranging from mild 
abnormalities in liver function to acute or chronic hepatitis and cirrhosis (25). 
In some severe cases, patients present with fulminant liver failure (1). 
In addition, WD patients often have reduced serum levels of the 
cuproenzyme caeruloplasmin as a result of rapid degradation of the copper 
free form of CP (26, 27). 
ATP7B is the key culprit gene for WD. Mutations in the ATP7B gene are 
closely linked to abnormal copper excretion, leading to excessive deposition 
of copper in the target organs (28). Almost 300 ATP7B mutations have been   
associated with WD development (29), of which up to 60% are missense 
mutations (30). Although most WD-causing mutations are rare, some are 
more common than others and account for a large portion of WD cases. In 
particular, the most prevalent ones are H1069Q in  Europe and North 
America, and R778L in southeast Asia (31).  
Wilson disease is characterized by extensive clinical heterogeneity, even 
among patients with the same mutations. The main differences lie in the age 
at presentation, severity of the disease, and the predominance of hepatic 
versus neurological symptoms (27).  
There are two therapeutic approaches to counter WD: copper chelation 
treatment using penicilammine or trientine (32),  and zinc therapy. Zinc 
induces enterocyte metallothionein, a cysteine-rich protein that is an 
endogenous metal chelator (24). Controversy exits as to which approach 
constitutes the more effective treatment regimen; however, when 
pharmacological treatments fail, or fulminant liver failure develops, liver 
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transplantation remains the only viable option (1). The major disadvantage of 
these therapies is the development of serious adverse effects. For instance,    
Cu-chelating agents induce serious toxicities, including hypersensitivity 
reactions, development of autoimmune disease, and bone marrow 
suppression. Zinc therapies are not exempt from adverse effects either. 
Therefore, there is a clear demand for novel WD treatment strategies. 
 
 
 
1.3 ATP7B: molecular architecture and function 
 
ATP7B belongs to the P-type ATPase family gene and is located on 
chromosome 13q.14.3 (33). The gene consists of 20 introns and 21 exons and 
several domains contribute to its critical function.  
ATP7B is a multispan transmembrane (TM) protein of 1465 aa that contains 
8 TM segments that form a channel for Cu translocation and 7 short luminal 
loops that connects these TM segments. The Cys-Pro-Cys (CPC) sequence 
motif, in the sixth transmembrane domain, is highly conserved across all 
ATPases. Moreover, since it is thought to be part of the intramembrane 
metal-binding site, studies suggest that it promotes copper transportation (34, 
35). In the N-terminal domain,  there are 6 metal-binding domains (MBDs), 
each of which contains the repetitive sequence motif GMXCXXC. The 
MBDs have high affinity for copper and play a major role in the acceptance 
of metal from the cytosolic copper transporter Atox1 by special protein-
protein interactions (36). Mutation analysis has proven that MBD5 and 
MBD6 can influence the catalysis and activation of ATP7B activity, whereas 
MBD1-4 have less impact on ATP7B (37).  
ATP7B contains an ATP-binding domain (N-domain or NBD), a 
phosphorylation domain (P-domain), and a phosphatase domain (A-domain) 
(38).  
NBD participates in domain-domain interactions (39) and contains  a unique 
and highly conserved amino acid motif, SEHPL, (histidine is an invariant 
residue) (40). Interestingly, although it is still unclear how SEHPL motif 
influences copper transport, its mutation (His1069Q) represents the most 
common WD mutation among Northern European populations (40).  
In the P-domain, a highly conserved motif, DKTGT, is crucial for the 
enzymatic phosphorylation occurring at the aspartic acid residue of the 
sequence (41). In particular, acyl-phosphate is the phosphorylated 
intermediate that drives protein conformational changes and copper transport 
to the opposite site of the membrane (42). In the A-domain, acyl-phosphate is 
dephosphorylated. The phosphatase activity is due to the Glu residue in the 
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Thr-Gly-Glu sequence motitf (TGE) of the A-domain. Dephosphorylation, 
instead, marks the completion of the cycle (20). 
Although the C-terminal domain is dispensable for catalysis, it is 
indispensable for maintaining protein stability and for regulating protein 
localization (34, 43). Wilson disease-associated mutations have been 
identified in the COOH terminus of ATP7B, indicating that this region has 
significant structural and/or regulatory properties. Indeed, some of these 
mutants are unstable, fail to be retained in the Golgi in low copper, and are 
unresponsive to the addition of copper (44).   
The structure of ATP7B  is schematically illustrated in Fig. 3. 
ATP7B is expressed in most organs and, to a much greater extent, in the  
liver. Intracellularly, ATP7B is mainly localized in the TGN (45, 46). More 
recent studies have indicated that ATP7B is redistributed from TGN to the 
late endosome/lysosome and plasma membrane of bile canaliculi when 
copper concentrations rise (47, 48). 
Therefore, ATP7B plays a double role in the liver. On one hand, it 
participates in copper transportation to TGN where copper is incorporated 
into ceruloplasmin, and, on the other hand,  it drives excess copper from the 
liver into the bile ducts for excretion (20) (Fig. 4).  
Excess copper facilitates ATP7B trafficking from the TGN to the lysosome, 
thereby facilitating the subsequent import of  copper into the lysomal lumen. 
Once the level of copper reaches a threshold value, toxic copper is excreted 
into bile via exocytosis (49). Moreover, increased copper levels can also 
stimulate ATP7B to move into the cytosolic vesicles, where copper may be 
“isolated” to protect cells from metal induced toxicity. Copper in vesicles is 
thought to be excreted by a similar mechanism as in the lysosomes 
(exocytosis) (50).  
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(Fei Wu et al., 2015) 
 
Fig. 3. Diagram of ATP7B. The metal-binding domain consists of 6 copper-
binding domains (MBD1-6), all with the conserved sequence motif CXXC. 
The transmembrane channel is composed of 8 discontinuous ion channels 
(Cylinder 1-8). The Cys-Pro-Cys (CPC) sequence motif confers metal ion 
selectively. ATP binds to the N-domain and the SEHPL motif located in the 
N-domain. The P-domain is required for phosphorylation of Asp in the 
sequence DKTGT. The A-domain is the place where the acyl-phosphate is 
dephosphorylated. 
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(Fei Wu et al., 2015) 
 
Fig. 4. Schematic illustration of copper transport and metabolism. 
HTCR1 delivers copper to the cytosol. Atox1 transfers the metal to TGN and 
is transported into the lumen with the help of ATP7B. Copper is then 
incorporated into ceruloplasmin secreted into the blood. The excess copper 
induces ATP7B trafficking from the TGN to the lysosome, from where it is  
transported to the lysosomal lumen. The excess copper is thus excreted into 
bile via exocytosis. A copper overload also stimulates ATP7B to move to 
cytosolic vesicles where copper is isolated and then released into the bile 
duct. 
 
 
 
1.4 H1069Q: the most frequent ATP7B mutation among Caucasians 
 
Nearly 500 mutations in ATP7B have been identified. Among these, more 
than 300 mutations have been found to be associated with WD (51). 
Mutations may occur at any position of the gene and the most common form 
of ATP7B mutation is missense mutation. Generally, frameshift and missense 
mutations are associated with a more severe phenotype of WD (52). 
It has been demonstrated that a genetic heterogeneity in patients with WD 
exists across various races and geographical regions (53). For example, 
H1069Q mutation of the ATP7B is more prevalent (about 60%) in WD 
patients of European origin, including Italians, Romanians, and Swedish,  
(54), whereas the R778L mutation is more common in East Asia (55). 
Therefore, both the variability in ATP7B mutation and gene heterozygocity 
make it difficult to use mutation signatures as a diagnostic tool (56). 
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WD-associated mutations affect the intracellular trafficking of ATP7B and/or 
its ability to transfer Cu across the membrane (1, 2, 57).  
In particular, H1069Q is defined as a mild mutation because it results in 
aberrant protein products that are strongly mis-targeted from the TGN 
towards the ER (Fig. 5) (58); however, this mutant still retains a residual Cu 
translocating activity (20 to 70% of WT ATP7B protein), most likely 
sufficient to prevent the disease only if the protein is correctly localized to 
the TGN (59-61). Moreover, ATP7B-H1069Q does not accumulate in 
transfected cells as its WT counterpart, suggesting a faster turn-over (62).  
The mutation alters the structure of the nucleotide binding domain (NBD) 
(62), conferring thermal instability to the protein and thus preventing it from 
passing the quality control checkpoints in the ER. Little is known about 
ATP7B oligomerization. However, studies suggest that this process does 
occur since the 3rd and 4th Cu-binding domains in the N-terminal portion of 
ATP7B aggregate in vitro (63). In particular, because the H1069Q mutation 
may affect the strength of interaction between the NBD and N-terminal 
domains, the 3rd and 4th Cu-binding domains are able to oligomerize and 
generate ATP7B-H1069Q aggregates. 
Taken together, these data suggest that the correction of the trafficking and 
localization of ATP7B-H1069Q should allow a substantial recovery of 
normal Cu metabolism. This finding offers a potential therapeutic application 
especially if the correction is applied in the late onset of the disease (at the 
age of 10-13 years) (64) before the manifestation of serious liver damage. 
 
  
 
 
Fig. 5. Intracellular trafficking of ATP7B and ATP7B-H1069Q mutant 
in the presence of low or high Cu concentration. 
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Multifunctional cellular properties of -crystallin protein  
 
The cellular chaperones are specialized proteins that not only help the 
nascent chains to attain native state (65-67), but also play a crucial role in the 
degradation and trafficking pathways. Moreover, the current view is that 
synthesis, folding, degradation and trafficking are strictly coordinated 
pathways that form the proteostasis network (68, 69). The rationale behind 
targeting chaperones in conformational diseases is that the overexpression (or 
repression) of the chaperone(s) most directly involved with a specific client 
protein might favourably induce homeostatic changes. 
Indeed, a previous work has shown that the cytosolic chaperone -crystallin 
(CRYAB or sHSP-B5) plays a central role in correcting/preventing improper 
aggregation, thereby rescuing folding of ATP7B-H1069Q and Frizzled4-
L501fsX533 (70). 
In particular, α-crystallin, the major protein in the lens, consists of two 
subunits, αA (HspB4) and αB (HspB5), which possess nearly 55% sequence 
homology between them (71). It belongs to the family of small heat shock 
proteins and contains a core “α-crystallin domain” (ACD). This domain is 
approximately 90 amino acids in length and is flanked by a variable 
hydrophobic N-terminal domain and a hydrophilic C-terminal domain (72) 
(Fig. 6). Both αA and αB are polydisperse oligomeric proteins, and their 
oligomeric size depends on their environment (73). α-crystallin represents 
approximately 40% of the protein in the human lens, where it exerts both a 
structural and functional role, with the αA and αB subunits present in 
approximately a 3:1 molar ratio (74). 
α-crystallin is also present in other tissues. Predominantly present in the lens, 
low levels of αA are also expressed in the retina, thymus, and spleen (75, 76). 
Instead, αB-crystallin is present in relatively large quantities in the retina, 
skeletal muscles, kidneys, and heart (77, 78).  
Being a member of sHSPs, CRYAB (175 aa) exhibits molecular chaperone-
like activity, called holdase activity (henceforth referred to as chaperone); 
more specifically, it binds to structurally perturbed proteins, preventing their 
aggregation in an ATP-independent manner (79).  
Besides its anti-aggregation activity, α-crystallins inhibit apoptosis induced 
by various factors. For example, in the lens epithelial cells, α-crystallins 
inhibit UVA-induced apoptosis through the regulation of PKCα, 
RAF/MEK/ERK, and AKT signaling pathways (80). In particular, αB-
crystallin has also been shown to inhibit cytochrome c release from 
mitochondria and the downregulation of Bcl-2 in H2O2-treated cells (81). 
CRYAB is also involved in other cellular functions such as cell cycle, 
differentiation, gene expression, interaction with proteasome, and prevention 
of cytoskeleton destabilization (Fig. 7). Intriguingly, recent reports have 
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shown that CRYAB is also secreted by a non-conventional secretory 
pathway, suggesting a protective function also outside the cell (82). 
Several mutations are associated with CRYAB. For example, the R120G 
mutation, identified in 1998, causes the loss of chaperone function and the 
formation of protein precipitates inside cells (83). Malfunctions of CRYAB 
are associated with myopathy, neuropathy, ischemia, cataract, and cancer 
(84).  
 
 
 
 
 
 
 
Fig. 6. Structural model of CRYAB protein and primary sequence of the 
3 domains of CRYAB. Dashed line, region of the protein for which no 
crystallographic data are available. The N-terminal, crystallin and C-terminal 
extension domains are indicated. In the crystalline domain, the 3 major 
peptides endowed of chaperone activity in vitro (73-85, 73-92 and 101-110) 
are indicated in blue, blue + green, and red, respectively. 
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(Nagaray et al., 2015) 
 
Fig. 7. α-crystallin inhibits several disease-contributing processes. 
 
 
 
1.6 Phosphorylation modulates both the structural and functional 
properties of CRYAB 
 
CRYAB exerts a variety of functions that most likely rely upon structural and 
functional changes, largely depending on post translational modifications 
(85). In particular, a major role in CRYAB function is played by 
phosphorylation occurring at 3 serine residues at positions 19, 45, and 59 of 
the N-terminal domain (86, 87). In fact, phosphorylation finely regulates 
CRYAB chaperone activity with multipass transmembrane proteins.  
In particular, our previous work reported the effect of CRYAB 
phosphorylation on ATP7B-H1069Q and FZ4-FEVR receptor in transfected 
cells (88). In FZ4-FEVR mutant, a frameshift mutation (L501fsX533) 
generates a shorter C-terminal cytosolic tail of the receptor that accumulates 
in the ER of transfected cells, thereby blocking it from reaching the plasma 
membrane as FZ4 wild-type (89). Through a site directed mutagenesis 
strategy to substitute 3 relevant serine residues with aspartic acid, it  is 
possible to mimic serine phosphorylation (90). The substitution with alanine 
residues in the same positions can prevent phosphorylation and is used to 
produce other types of mutants: the single and double pseudo-phosphorylated 
mutants.  
The main results of my research project indicate that mimicking 
phosphorylation of serine 19 and 45, either singularly or in combination, 
causes loss of CRYAB chaperone activity, whereas the single 
phosphomimetic S59 has no such effect. On the other hand, pseudo-
phosphorylation on serine 59 prevents the 19/45 phosphorylation-dependent 
inhibitory effect. However, this protecting effect is lost when all 3 serine 
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residues are simultaneously pseudo-phosphorylated. Moreover, the inhibition 
of chaperone activity does not correlate with the reduction of the 
oligomerization state of CRYAB, suggesting a direct role of phosphorylation 
in modulating both the structure and the function of the protein (88). 
 
 
 
1.7 CRYAB-derived peptide: therapeutic perspectives for conformational 
diseases 
 
Experimental demonstration of the beneficial effects of CRYAB clearly 
opens exciting therapeutic perspectives for several diseases of protein 
aggregation. However, its systemic administration has limitations owing to 
the specificity of action, rapid clearance of the protein, targeted delivery, and 
off-target effects. 
Even more exciting has been the discovery that small peptides of both 
CRYAB and CRYAA also exhibit chaperone and anti-apoptotic activities. 
These peptides show remarkably similar activities to the whole protein. 
Furthermore, unlike the whole protein, peptides are easier to produce and are 
more amenable to manipulations for improvements in delivery and activities 
(79). 
In particular, studies in vitro have demonstrated that isolated CRYAB 
derived  peptides corresponding to residues 73-85 and 101-110 of the 
crystallin domain have anti-fibril formation activity (91), and that peptide 73-
92 prevents aggregation and precipitation of denaturing alcohol 
dehydrogenase (92) (Fig. 6). 
Most intriguingly, peptide 73-92 enters human fetal retinal pigment cells in 
culture via the sodium-coupled oligopeptide transporters 1 and 2 and protects 
them from apoptosis induced by oxidative stress. Even better protective 
results have been obtained with nanoparticles-containing peptides that are 
taken up by the cells (93). Moreover, this peptide, which enters via a lipid 
transporter, protects CHO and human lens pigment cells from thermal-stress 
induced apoptosis. Remarkably, intraperitoneal injection of the peptide 
inhibits cataract development in selenite-treated rats. In particular, the 
injected peptide reaches the lenses and inhibits oxidative stress, protein 
insolubilization, and caspase activity (94).  
Although it remains to be formally proven that the CRYAB-derived peptide 
acts with the same mechanism as its full-length counterpart overexpressed in 
cells by transfection (70), much evidence supports the view that the peptide 
does mimic the effect of the full-length protein in all the parameters analyzed 
in different studies. In addition, evidence shows that the peptide has a 
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surprising ability to enter cells and to cross the blood acqueous barrier (93, 
94).  
Thus, these findings strongly sustain the exciting hypothesis that a CRYAB-
derived peptide can effectively function as the full-length chaperone in live 
cells to restore ATP7B-H1069Q function. 
 
 
 
1.8 Wilson disease models 
 
The molecular mechanisms underlying WD associated with H1069Q 
mutation have not yet been confirmed in a proper H1069Q cell system. 
Indeed, although human hepatocytes remain the gold standard for the 
molecular analysis of WD in the liver, they do not represent a realistic option 
owing to the scarce number of cells in a biopsy and their inability to 
proliferate in vitro.  
Lower eukaryotic models, like ccc2 yeast, and the widely studied mammalian 
cell line, Chinese Hamster Ovary (CHO) cells, lacking ATP7B expression, 
represent useful systems to study the properties of ATP7B mutants. However, 
the problem with these cellular lines is that differences in species and organ 
source make it difficult for scientists to translate the results into human liver. 
On the other hand, human hepatoma cell lines are excellent cellular platforms 
to study ATP7B and its activity in Cu homeostasis, as indicated by the most 
commonly used hepatic cell line, Hep-G2. However, the fact that Hep-G2 
and Huh-7, another human hepatic cell line, express endogenous and 
functional ATP7B may indeed hamper the study of  the role of H1069Q 
mutation (95). Therefore, the use of heterologous or hepatoma-derived cell 
lines in which the mutant is overexpressed has obvious limitations owing to 
different genetic landscapes and proteostatic networks. 
This obstacle could be circumvented by adopting a mammalian model for 
this form of WD, but unfortunately no such model has yet been generated. 
Recently, H/Q substitution has been achieved in drosophila ATP7 (dATP7). 
However, a major issue of this system is that insects do not have livers and 
dATP7 functions resemble those of mammalian ATP7A rather than those of 
ATP7B. In fact, dATP7 suppression leads to a severe Cu deficiency similar 
to Menkes phenotype in humans. Moreover, this system fails to recapitulate 
human disease because of genetic and epigenetic variability. 
Therefore, the generation of cellular systems that would bear close 
similarities to patient-derived cells represents one of the most interesting 
therapeutic approaches to investigate the molecular features of H1069Q 
mutation and to screen disease-correcting strategies.  
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2. AIM OF THE THESIS 
 
In this thesis, I will discuss the identification of new therapeutic perspectives 
for the most frequent ATP7B mutation causing Wilson Disease (WD). In 
particular, I will address the two pivotal aims of my PhD  project: 1) the 
identification and exploitation of active peptides for therapeutic purposes in 
WD; 2) the generation of an isogenic cell model based on iPSCs obtained 
from skin fibroblasts of a homozygous WD patient and his mother, used as 
control, and their differentiation in hepatocyte-like cells (HLCs). 
 
Regarding the first aim, in an attempt to find new and more efficient  
treatments for WD patients, we explored the pharmacologically active 
peptides present in cells overexpressing the H1069Q mutation of ATP7B. 
Such line of research was inspired by insightful evidence demonstrating that 
ATP7B-H1069Q retains a residual Cu transport activity despite being 
incapable of reaching its physiological destination and having an impaired  
Cu-dependent trafficking, due to its mislocalization in the ER. Therefore, 
evidence that B-crystallin activity rescues localization and trafficking in 
response to Cu overload in ATP7B-H1069Q transfected cells generated our 
great interest in investigating the therapeutic potential of smaller portions of 
B-crystallin. In particular, we examined peptide 73-92 for its anti-
aggregation and anti-apoptotic activities in vitro, in cultured cell, and 
experimental animals. 
To assess the beneficial effects of the synthetic peptide 73-92, we tested it in 
COS-7 cells transfected with GFP-ATP7B WT or mutant and in a stable 
human Hep-G2 KO cell line for the expression of ATP7B infected with an 
adenovirus carrying the previously mentioned constructs. 
 
Regarding the second aim, we endeavored to create a cellular system that 
would allow us to delve deeper into the molecular dynamics responsible for 
the pathogenesis caused by ATP7B-H1069Q. Thus, to this end, we generated 
an isogenic cell model-based on iPSCs obtained from skin fibroblasts of a 
homozygous patient and his mother, used as control, and differentiated them 
into HLCs. Indeed, the novelty of our work lies in having shifted from the 
commonly used heterologous or hepatoma-derived cell lines overexpressing 
the mutant to a cellular model that would much more closely resemble a WD 
patient with isogenic expression of ATP7B-H1069Q. Remarkably, this new 
cell model gave us the opportunity to circumvent the use of cellular systems 
bearing a proteostatic network different from patient-derived cells, as well to 
overcome the limitations of hepatocytes from liver biopsies due to their 
scarce availability and inability to proliferate in vitro. 
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3. MATERIALS AND METHODS 
 
cDNA cloning and plasmid construction 
 
cDNA encoding CRYAB (ID: NM_001885.1) cloned into pCMV6-XL5 
vector plasmid was obtained from Origene. To obtain the construct 3xFLAG-
CRYAB, the cDNA coding for CRYAB was amplified from pCMV6-XL5 
plasmid by PCR using the following oligos containing HindIII/XbaI flanking 
restriction sites and cloned into p3xFLAG-CMV-7.1: 
 
- Fw (HindIII):59-AAGCTTATGGACATCGCCATCCACCACCC-39;  
- Rv (XbaI): 59-TCTAGACTATTTCTTGGGGGCTGCGG-39. 
 
To obtain the construct 3xFLAG-CRYAB (R120G) in which the R120 was 
substituted with a glycine (G), the construct 3xFLAG-CRYAB was used as a 
template and site direct mutagenesis was performed according to the 
manufacturer instructions (Roche) using the following oligos: 
  
- Fw: 59-CTCCAGGGAGTTCCACGGGAAATACCGGATCCCAG-
39;  
- Rv: 59-GTGGAACTCCCTGGAGATGAAACC-39. 
  
To obtain the construct HA-CRYAB, the cDNA coding for CRYAB was 
amplified from pCMV6-XL5 plasmid by PCR using the following oligos 
containing HindIII/XbaI flanking restriction sites and cloned into pCDNA3 
expression vector (Invitrogen): 
  
- Fw (EcoRI): 59-GAATTCATGGACATCGCCATCCACCACCC-39; 
- Rv (XhoI): 59-CTCGAGCTATTTCTTGGGGGCTGCGG-39.    
 
DNA of ATP7B and ATP7B-H1069Q GFP-tagged at the N-terminus was 
provided by Svetlana Lutsenko (John Hopkins Medical School, Baltimore, 
MD) and by Dominik Huster (Otto-von-Guericke-University, Magdeburg, 
Germany). 
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Cloning strategy to generate HA-tagged CRYAB domains 
 
The representative scheme of cloning strategy used in this study is shown in 
Fig. 8. 
N-terminal, -crystallin, and C-terminal domains were amplified using the 
Expand High Fidelity PCR System (Roche) and specific primers: 
 
N-terminal domain  
FW: 5’-GAATTCATGGACATCGCCATCCACC-3’ 
REV: 5’CTCGAGCTATGAGAGAGTCCAGTGTCAAACC-3’ 
 
-crystallin domain  
FW: 5’-GAATTCCTCTCAGAGATGCGCCTGG-3’ 
REV: 5’-CTCGAGCTAATTCACAGTGAGGACCC-3’ 
 
C-terminal domain  
FW: 5’-GAATTCCCAAGGAAACAGGTCTCTG-3’ 
REV: 5’-CTCGAGCTATTTCTTGGGGGCTGC-3’ 
 
The forward primers contain the restriction enzyme EcoRI recognition site, 
while the reverse primers contain the restriction enzyme XhoI recognition 
site. In the reverse primers used for the amplification of N-terminal and -
crystallin domains is also present a stop codon. Restriction enzymes EcoRI 
and XhoI recognition sites are compatible with the multiple cloning sites on 
the HAN(I)-pcDNA3 expression vector. The amplified gene was cloned into 
pCR 2.1-TOPO cloning vector (Invitrogen) and transformed into TOP10 
Escherichia coli (E. coli) cells. Transformed cells were selected on a LB 
(Luria-Bertani) plate containing 100 µg/mL ampicillin at 37°C for 16-18 h. 
Positive transformants were inoculated into LB broth containing 100 µg/mL 
ampicillin for plasmid propagation. Plasmid was isolated and the presence of 
the DNA fragment of interest was determined by restriction enzyme digestion 
and DNA sequencing. The TOPO vector containing the DNA fragment of 
interest and the expression vector were then digested with the same enzymes 
(EcoRI and XhoI) to generate the same sticky ends. The digestion products of 
both the DNA of interest and the expression vector were ligated at room 
temperature for 5 min using the Rapid DNA Ligation Kit (Roche). Ligated 
mixture was transformed into TOP10 E. coli cells selected with the same 
strategies as those described above. 
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Fig. 8. Overview of gene cloning. FOI was amplified using gene specific 
primers incorporated with restriction enzyme digestion sites. The PCR 
product was cloned into pCR-2.1 TOPO vector. The gene was digested from 
the TOPO vector and ligated into an expression vector that was similarly 
digested. The ligated mixture was then transformed into an appropriate 
bacteria expression strain. 
 
 
Cell culture 
 
Cell lines were maintained in 5% CO2 at 37°C in a humidified chamber. 
COS-7 (monkey kidney fibroblast-like cells) cell line was routinely grown in 
Dulbecco’s modified essential medium (DMEM), containing 10% fetal 
bovine serum (FBS) and supplemented with 1% L-Glutamine and 1% 
penicillin/streptomycin.  
Hep-G2 (human hepatocellular carcinoma) ATP7B knock-out cells, kindly 
provided by Roman Polishchuk, were cultured in Roswell Park Memorial 
Institute (RPMI) medium (Lonza) containing 10% fetal bovine serum (FBS) 
and supplemented with 1% L-Glutamine and 1% penicillin/streptomycin. 
ATP7B knockout was achieved by ZFN directed mutagenesis using Chandok 
et al’s method (95). 
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Transfection 
  
COS-7 cells were cultured on coverslips in a 12-multiwell plate and, after 24 
h, were transfected with X-tremeGene HP (Roche, Milan, Italy), according to 
the manufacturer’s instructions, and using a 2:1 X-treme:DNA ratio. 
 
 
Viral transduction 
 
Hep-G2 KO cells were cultured on coverslips in a 24-multiwell plate, and, 
after 24 h, were infected with an adenovirus carrying GFP-ATP7B-H1069Q 
using a MOI= 700. Human adenovirus type 5 (dE1/E3) was produced by 
Vector Biolabs in HEK 293 as packaging cells and CMV promoter drives the 
expression of GFP-ATP7B-H1069Q. 
 
 
Peptide treatment 
 
CRYAB peptide (Pept1) and control peptides (inverted and scrambled 
sequence, respectively) were first chemically synthesized by GL Biochem 
(Shanghai, China) and then resuspended in H2O to obtain a final 
concentration of 5 mM each. Synthetic peptides were either labeled or 
unlabeled with TAMRA to the side chain of amino group of Lysine residues 
at the carboxy or amino terminal ends. In all the experiments performed, 12.5 
M of each peptide was dissolved in a solution, composed of sterile water 
(25%) and culture medium (75%), and then added to the cells.  
 
 
Immunofluorescence 
 
COS-7 or Hep-G2 KO cells were seeded on coverslips. After 48 h from 
transfection or infection and after 24 h from treatment with 12.5 µM of both 
TAMRA-labeled or unlabeled Pept1 or Ctrl Pept, cells were fixed in PBS 1x-
formaldehyde 3.7% for 30 min at room temperature and washed with PBS 
1x. Then, they were permeabilized with 0.1% Triton-PBS 1x, treated with 
PBS 1x-BSA 1% for 15 min, and newly washed with PBS 1x. After that, they 
were subjected to indirect immunofluorescence staining. 
Thus, the cells were incubated for 1 h at room temperature with the following 
primary antibodies: mouse monoclonal anti-FLAG (1:2000, Sigma), mouse 
monoclonal anti-HA (1:2000, Sigma), rabbit anti-GOLGA 2 (1:100, Sigma), 
and mouse monoclonal anti-LAMP1 (1:200, DSHB). Next they were washed 
with PBS 1x 3 times and incubated with the corresponding secondary 
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antibodies conjugated with Alexa Fluor 488, Alexa Fluor 568, and Alexa 
Fluor 633 (1:400, Life Technologies) for 45 min at room temperature. They 
were occasionally stained with Dapi (1:500, Sigma) and mounted in Mowiol.  
Finally, they were visualized with a 63x Plan-Apo/1.4 NA Oil lens using 
LSM510 Meta. 
 
 
MTT assay 
 
COS-7 cells or Hep-G2 KO cells were seeded in 96-well plates for 24 h and 
then exposed to 12.5 M of Pept1 or Ctrl Pept. During the peptide treatment, 
10 l of 5 mg/ml MTT solution was added to each well for 4 h at 37°C. After 
removal of the medium, 100 l of 0.1 M HCl in Isopropanol was added to 
each well to dissolve formazan crystals. The absorbance at 570 nm was 
determined using the SYNERGY H1 microplate reader (Bio-Tek 
Instruments, Inc, Winooski, VT, USA). 
 
 
Differential centrifugation 
 
COS-7 cells were plated in p60 dishes. After 24 h, cells at 80% confluence 
were treated with TAMRA-labeled Pept1 or Ctrl Pept. After 20 h, the cells 
were resuspended in lysis buffer (10 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 
mM EDTA ph 8.0, and protease inhibitors 1x), incubated 30 min on ice and 
then lysed by sonication (2 pulses of 3 seconds; intensity: 2). The samples 
were then centrifuged at 16.000xg at 4°C for 30 min, the pellets (P16) 
resuspended in lysis buffer, and the supernatants centrifuged at 100.000xg at 
4°C for 30 min (S100). Finally, the pellets (P100) were resuspended in lysis 
buffer (supplemented with 1% Triton). All the pellets and the supernatants 
obtained from the 100.000xg centrifugation were analyzed by 
spectrofluorimeter. The main phases of subcellular fractionation are 
described in Fig. 9. 
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Fig. 9. Generation of P16, S100, and P100 subcellular fractions by 
differential centrifugation. 
 
 
Copper treatment 
 
COS-7 cells, seeded on coverslips in 12-multiwell plates, were transfected 
with pEGFP-C1-ATP7B WT or pEGFP-C1-ATP7B-H1069Q and treated 
with Pept1 or Ctrl Pept. After 48 h, the culture medium was changed to a 
fresh one containing either 200 µM of CuSO4 or 500 µM of BCS. After 2 h, 
cells were subjected to indirect immunofluorescence procedure as above. 
Single confocal images were acquired at 63X magnification on a LSM510 
Meta confocal microscope (Carl Zeiss, Jena, Germany). 
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FLIM-FRET 
 
COS-7 cells were cultured on coverslips in 12-multiwell plates. After 24 h, 
cells were transfected with pEGFP-C1-ATP7B WT or pEGFP-C1-ATP7B-
H1069Q as above. Twenty-four hours after transfection, the cells were 
treated with 12.5 µM of both TAMRA-Pept1 or TAMRA-Ctrl Pept; Then, 48 
h post transfection, cells were fixed with paraformaldehyde (2%) for 20 min. 
For FLIM-FRET analysis, TCS SMD SP5 Leica microscope equipped with 
FLIM module was used. 
 
 
iPSC generation and differentiation 
 
To obtain primary fibroblasts (authorization # 271/16 of the Ethical 
Committee of the University of Naples Federico II), skin biopsies from a 
patient and the healthy control (patient’s mother) were cut (1 mm x 3 mm) 
into small pieces using a scalpel blade and cultivated on cell culture dishes in 
fibroblast medium consisting of DMEM supplemented with 20% FBS, 2 mM 
L-glutamine, and 1% penicillin and streptomycin (all from Invitrogen). 
To generate iPSCs, 1 × 10
6
 fibroblasts were transfected with a total of 1 μg of 
each of the following episomal plasmids: pCXLE-hOCT3/4-shp53-F, 
pCXLE-hSK, pCXLE-hUL (all from Addgene) (96). Electroporation was 
carried out using a Nucleofector™ 2b Device (Lonza) by employing NHDF 
Nucleofector Kit (Lonza), following the manufacturer’s instructions. Four 
days later, cells were plated on mitomycin inactivated fibroblasts (feeder) and 
cultivated in hES medium as follows: KO-DMEM, 20% Knock-out serum 
replacement (KOSR), 1x Glutamax, 1x μM nonessential amino acids, 50 
U/ml (penicillin and 50 mg/ml streptomicin), 100 μM 2-mercaptoethanol (all 
from Invitrogen), and 10 ng ml-1 bFGF (Peprotech). After 20-22 days, 
individual iPSC colonies were isolated and expanded for multiple passages 
(>5) on Matrigel (BD Biosciences) in mTeSR medium (Stem cell 
technologies) to remove feeder layer. 
 
 
Generation of HLCs from iPSCs 
 
To generate hepatocytes from both control and patient iPSC clones, we 
employed an already described method that allows efficient production of 
HLCs (97). Briefly, iPSC clones were plated on Matrigel and cultivated for 
20-22 days. During this culture period, the medium composition  was 
changed as follows: 5 days in RPMI media supplemented with B27 and 
100ng/ml of Activin A (R&D), 5 days in RPMI media supplemented with 
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20ng/ml BMP4 (R&D) and 10ng/ml bFGF (Preprotech), 5 days in RPMI-
B27 supplemented with 20ng/ml hepatocyte growth factor (HGF, Invitrogen) 
and finally further 5-7 days in hepatocyte culture medium (Lonza) 
supplemented with 20ng/ml oncostatin M (Invitrogen). 
 
 
Immunofluorescence of control and patient iPSCs and HLCs 
 
hiPSCs were fixed in 4% paraformaldehyde and permeabilized with 0.2% 
TX-100 in 10% FBS/1% BSA in 1x PBS for 7 min at room temperature;  
non-specific signals were blocked in 10% FBS/1% BSA in 1x PBS for 30 
min at room temperature. Thus, the cells were incubated with primary 
antibodies in 10% FBS/1% BSA in 1x PBS overnight at 4°C. The primary 
antibodies used were the following: anti-Oct4 (1:500, Santa Cruz), anti-
Nanog (1:500, Cell Signaling), anti- alpha-fetoprotein (1:400, Abcam), and 
anti-albumin (1:100, Dako). Following primary antibody incubation and 
washes in 1x PBS, the cells were incubated with Alexa- Fluor 488 or 594 
secondary antibodies (1:400, Molecular Probes) and nuclei were stained with 
Dapi (1:5000, Calbiochem). Cells were then visualized with a 20×/0.40 (dry 
lens) objective using an inverted microscope (DMI4000, Leica 
Microsystems) at room temperature in 1x PBS. The images were captured 
with a digital camera (DFC365 FX, Leica Microsystems) using LAS-AF 
software (Leica Microsystems). 
 
 
Preparation of cell extracts, SDS-PAGE, and Western blot analysis 
  
After 20 days of differentiation, HLCs from control and patient iPSCs were 
treated with or without 100 mM cycloheximide (Sigma) for the indicated 
time period. Cells were lysed with lysis buffer containing 10 mM Tris-HCl 
pH 7.4, 150 mM NaCl, 1 mM EDTA pH 8, 1% Triton X-100 supplemented 
with cock-tail protease inhibitors (Roche Diagnostics) and protein 
concentration was determined by Bradford assay (Bio-Rad). Denaturation 
and reduction of protein samples for SDS-PAGE were performed at 37°C for 
30 min. For each sample, 50 ug of total protein was loaded into 8% SDS gel 
and blotting was performed using a 0.45 μm nitrocellulose membrane (GE 
Healthcare). The blots were blocked for 1 h with 5% non-fat dry milk 
prepared in TBST (10 mmol/L Tris (pH 8), 150 mmol/L NaCl, 0.1% Tween 
20) and subsequently incubated with primary antibody for ATP7B (rabbit 
polyclonal, 1:5000, Abcam), actin (rabbit polyclonal, 1:1000, Sigma) or 
vinculin (mouse monoclonal, 1:1000, Santa Cruz) as a protein loading 
control, for 1 h at room temperature. Blots were washed with TBST 3 times 
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and further incubated for 1 hour with secondary antibodies HRP-conjugated 
goat anti-rabbit (Santa Cruz) and anti-mouse IgG (Santa Cruz). Bound 
antibodies were detected by the ECL system (Santa Cruz). Densitometric 
analysis was performed using ImageJ 1.47v software. 
 
 
Confocal immunofluorescence analysis 
 
Control and patient HLCs, seeded on m-slide 8 Well (Ibidi) chamber, were 
fixed in 4% paraformaldehyde for 20 min, washed in 1x PBS, and 
permeabilized with 0.1% TX-100 in 1x PBS for 6 min at room temperature. 
Non-specific signals were blocked in 10% FBS/1% BSA in 1x PBS (blocking 
solution) for 30 min at room temperature. The cells were then incubated for 1 
h with the following primary antibodies: rabbit anti-ATP7B (1:100), rabbit 
anti-BCAP31 (1:100, Proteintech), mouse monoclonal anti-Golgin-97 (1:400, 
Invitrogen), mouse monoclonal anti-KDEL (1:200, Enzo Life Sciences), and 
mouse monoclonal anti-LAMP1 (1:200, DSHB). The cells were then washed 
3 times in PBS and incubated with the corresponding secondary antibodies 
conjugated with either Alexa Fluor 488 or Alexa Fluor 568 (Life 
Technologies) for 45 min, occasionally stained with Dapi (Sigma-Aldrich).  
Cells were visualized with a 63x Plan-Apo/1.4 NA Oil lens using LSM510 
Meta or LSM710 confocal microscopes. 
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4.  RESULTS 
 
4.1 -crystallin domain is able to rescue the physiological localization of 
ATP7B-H1069Q 
 
Our results extend our recent findings demonstrating that CRYAB rescues 
ATP7B-H1069Q localization (70). A few years before that, another study had 
also demonstrated that isolated domains of CRYAB did maintain some level 
of chaperone activity in vitro (98). It is on the basis of this insightful 
evidence that we decided to explore even further whether a specific region of 
the whole protein could retain this functional role. 
To explore this possibility, we dissected CRYAB in its main domains 
designing a suitable cloning strategy. In brief, the N-terminal (NTD) and -
crystallin (CD) domains, along with the C-terminal (CTE) extension 
(residues 1-66, 65-146, 148-175, respectively), were cloned in a 
HAN(I)pcDNA3 vector to generate HA-tagged polypeptides. Full-length 
CRYAB was cloned in the same vector. Each domain was functionally tested 
by co-transfecting COS-7 cells with ATP7B-H1069Q and its activity was 
compared to that of HA-CRYAB under the same cellular conditions. 
Transfection of ATP7B alone was used as positive control.  
As demonstrated by confocal immunofluorescence analysis, no rescue effect 
occurred in the presence of the N-terminal and C-terminal constructs, as 
revealed by the reticular signal of ATP7B-H1069Q. In contrast, -crystallin 
domain clearly mimicked the activity of the full-length protein, as confirmed 
by measuring the overlap of the GFP signal with GOLGA 2-blue staining 
(Golgi marker), calculated as Pearson’s R value (Fig. 10).  
Such finding strongly suggests that the -crystallin domain retains the 
chaperone activity of the whole protein. Equally important, it also indicates 
the possibility of exploring the potential sequences in the -crystallin domain 
that preserve these properties to test smaller molecules against the most 
frequent mutation causing Wilson disease. 
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Fig. 10. -crystallin domain corrects localization of ATP7B-H1069Q 
from the ER to the TGN. COS-7 cells were transfected to express GFP-
tagged ATP7B or ATP7B-H1069Q and co-transfected with either HA-
CRYAB or its domains (HA-NTD, HA-CD and HA-CTE respectively). Anti 
GOLGA 2 protein antibody was used to visualize the Golgi complex.  
The histogram below shows the percentage of ATP7B or ATP7B-H1069Q 
transfected cells exhibiting ER, Golgi, and ER plus Golgi staining (average ± 
s.d., n=20 cells from 2 independent experiments). Scale bar: 10 m. 
 
 
 
4.2 CRYAB-derived peptide does not affect cell viability 
 
The discovery of mini-chaperones, i.e., peptides derived from the -crystallin 
chaperone region, has created new therapeutic perspectives to counteract 
diseases of protein aggregation (99). In particular, it has been previously 
reported that CRYAB peptide corresponding to residues 73-92 exhibits anti-
aggregation and anti-apoptotic properties into cultured cells and in 
experimental animals (93, 94). Based on these findings, we used the synthetic 
peptide 73-92 (which we called Pept1) in our cellular models to investigate 
whether it could revert the WD phenotype as efficiently as the -crystallin 
domain and the full-length protein. To verify the specificity of action, we 
used 2 control peptides with inverted and scrambled sequences. The peptides 
were labeled or unlabeled with TAMRA at the side chain amino group of the 
lysine residue at the C- or N- terminal ends (Fig. 11). 
Our next step was then to test the toxicity of all peptides in 2 different cell 
lines: COS-7 and human Hep-G2 KO for ATP7B expression. Thus, we 
performed an MTT assay by incubating cells with 12.5 M of each peptide 
for 72, 96 and 120 h. We observed the peptides did not impair cell viability in 
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either cell line even after prolonged peptide exposure, compared to untreated 
cells (Fig. 12). 
 
 
 
 
 
 
Fig. 11. Synthetic peptides used in the experimental plan. The box shows 
αB-crystallin-derived peptide sequence (Pept1) and the control peptides with 
inverted or scrambled sequence, labeled or unlabeled with TAMRA at the 
side chain amino group of Lys residue at the carboxy or the amino terminal 
ends. 
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Fig. 12. Pept1 and Ctrl Pept do not impair cell survival. Cell viability of  
COS-7 and Hep-G2 KO cells was determined by MTT assay after 72, 96 and 
120 h of peptide exposure. No significant differences were observed in the 
percentage of cell viability between cells incubated with Pept1 or Ctrl Pept 
and control. MTT data are represented as mean ± s.d. of at least 3 
independent experiments. 
 
 
 
4.3 CRYAB peptide is mainly cytosolic and associated with vesicular 
compartments in a time-dependent manner 
 
Since we found that both Pept1 and control peptide did not affect cell 
viability, we asked whether these peptides could be internalized by cells.  
To verify this hypothesis, COS-7 cells were incubated with 12.5 M of  
TAMRA-labeled Pept1 and control peptide for 1, 4 and 20 h. An antibody 
against LAMP1 protein was used as a lysosomal marker.  
Confocal immunofluorescence images showed that the peptide fluorescent 
signal was mainly cytosolic and partially colocalized with the lysosomal 
marker after 20 h (Fig. 13). This result strongly suggests that peptides are 
somehow able to enter COS-7 cells, albeit the entry mechanism remains 
unclear. 
Furthermore, we fractionated, through differential centrifugation, COS-7 
cellular extracts treated with TAMRA-conjugated peptides for 20 h. The 
subcellular fractions considered in the analysis were P16, S100, and P100. 
Fluorescence emission of each fraction was analysed by spectrofluorimetry. 
We found about 60% of peptide in the S100, confirming the 
immunofluorescence data about a cytosolic localization of the peptide. 
However, the presence of smaller amounts both in P16 and P100 fractions 
suggests an association of the peptide with vesicular compartments, as 
indicated by the colocalization with LAMP1 (Fig. 14). Overall, CRYAB 
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peptide enters the cells where it is mainly localized in the cytosol and 
partially in the vesicular structures in a time-dependent fashion.   
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Fig. 13. CRYAB peptide and control peptide are internalized by COS-7 
cells. COS-7 cells were incubated with 12.5 M of TAMRA-labelled Pept1 
and Ctrl Pept at the indicated times. Confocal immunofluorescence analysis 
was performed using an anti-LAMP1 protein antibody to visualize the 
lysosomes. Peptide fluorescent signal was evident in the cytosol after about 4 
h and co-localization with LAMP1 was predominantly after 20 h. Scale bar: 
10 m. 
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Fig. 14. CRYAB peptide localizes mainly in the cytosolic fraction of 
COS-7 cells. Cells were incubated with 12.5 M of TAMRA-labeled Pept1 
and Ctrl Pept for 20 h, lysed, and then separated into subcellular fractions 
using variable centrifugation, as indicated in the scheme. Fluorescence 
emission of each fraction was determined by spectrofluorimeter and reported 
as percentage of P16, S100, P100 in the graph below. 
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4.4 Comparing the effect of CRYAB peptide on the localization of ATP7B-
H1069Q in COS-7, Hep-G2 KO, and Huh-7 cell lines 
 
COS-7 cells were transfected to express the GFP-tagged ATP7B localizing 
with GOLGA 2-blue staining (Golgi marker) or ATP7B-H1069Q whose 
signal was clearly reticular. Intriguingly, we found that in cells expressing 
ATP7B-H1069Q and co-transfected with full-length CRYAB or treated with 
12.5 M of Pept1 (labeled or unlabeled with TAMRA) for 24 h, ATP7B-
H1069Q was able to rescue the Golgi localization. No such effects were 
observed in the presence of either CRYAB-R120G or control peptide. Under 
both conditions, the mutant was mainly retained in the ER (Fig. 15).  
This evidence was strongly supported by quantitative analysis of ATP7B or 
ATP7B-H1069Q transfected cells exhibiting ER, Golgi, or ER plus Golgi 
staining. In the presence of the CRYAB peptide, percentage of cells showing 
a Golgi signal of the mutant is prevalent and comparable to that of cells co-
transfected with full-length CRYAB. Furthermore, we confirmed the rescue 
activity of Pept1 on the mutant by measuring the overlap of GFP signal with 
GOLGA 2-blue staining, calculated as Pearson’s R value (Fig. 15). 
In addition, although COS-7 cell line is easy to manipulate, we decided to 
perform the same experimental design in cellular models that would reflect 
much more closely the pathophysiology of a WD. In particular, we used Hep-
G2 KO and Huh-7 because they are excellent cellular platforms to study Cu 
homeostasis (95). The reason we chose a stable human Hep-G2 KO cell line 
for ATP7B expression was to abolish the risk of endogenous expression of 
ATP7B (95). In brief, we performed the same experimental plan and peptide 
treatment conditions in Hep-G2 KO and Huh-7 (Tackling the Most Frequent 
Wilson Disease-Causing ATP7B Mutation: Mechanism of Rescue by B-
Crystallin and its Derived Peptide, Ph.D. Michela Ciano). However, Huh-7 
were transfected with the same constructs used for COS-7 cells, whereas 
Hep-G2 KO were infected with an adenovirus carrying GFP-ATP7B-
H1069Q given that viral infection considerably increases the population of 
cells expressing the mutant protein compared to the DNA transfection. 
Colocalization of GFP-ATP7B-H1069Q with the Golgi marker was 
generated as Pearson’s R value.   
As expected, confocal immunofluorescence and colocalization analysis (Fig. 
16) in Hep-G2 KO fully confirmed those obtained in COS-7 cells and Huh-7 
(data not shown). CRYAB peptide was able to correct the localization of the 
mutant, clearly suggesting the beneficial effects and the specificity of this 
peptide in different cellular disease models.   
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Fig. 15. Pept1 corrects localization of ATP7B-H1069Q from the ER to 
the Golgi complex. COS-7 cells were transfected to express GFP-tagged 
ATP7B or ATP7B-H1069Q and co-transfected with either 3xFlag-CRYAB 
or CRYAB-R120G or incubated with Pept1 and Ctrl Pept (12.5 M), in the 
presence or absence of TAMRA, for 24 h post-transfection. Subsequently, 
the cells were processed for confocal immunofluorescence analysis using an 
anti-GOLGA 2 protein antibody to visualize the Golgi complex. In the 
presence of full-length CRYAB or both forms of Pept1, ATP7B-H1069Q 
fluorescence signal mainly localized with the Golgi marker, whereas it was 
clearly reticular in the cells co-transfected with CRYAB-R120G or treated 
with Ctrl Pept. Scale bar: 10 μm. 
The histogram below shows the percentage of ATP7B or ATP7B-H1069Q 
transfected cells exhibiting ER, Golgi complex, and ER + Golgi complex 
staining (mean ± s.d., n=25 cells from 2 independent experiments). 
Colocalization of GFP and GOLGA 2 signals was determined with the 
ImageJ colocalization plugin and the obtained Pearson's R value is shown on 
the right.  
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Fig. 16. Rescue activity of Pept1 on ATP7B mutant in Hep-G2 KO. Hep-
G2 KO cells were infected with GFP-ATP7B-H1069Q. After 24 h, cells were 
treated with 12.5 μM of either Pept1 or Ctrl Pept conjugated or unconjugated 
with TAMRA. In the presence of Pept1, ATP7B-H1069Q was rescued to the 
Golgi; instead, in the presence of Ctrl Pept, ATP7B-H1069Q was retained in 
the ER. Colocalization of GFP and GOLGA 2 signals was determined with 
the ImageJ colocalization plugin; the obtained Pearson's R value is shown on 
the right. Scale bar: 10 μm.  
 
 
4.5 Golgi-corrected ATP7B-H1069Q redistributes to post Golgi vesicles in 
response to copper overload 
 
Another important issue was to investigated whether Pept1 could restore 
post-Golgi trafficking activity of the mutant in response to increased copper 
concentrations. 
To address this question, we designed the same immunofluorescence 
experiment previously described in COS-7 cells. In brief, before fixation, 
cells were incubated for 2 h in a medium containing either 200 M of 
cupronic sulphate (CuSO4) or 500 M of bathocuproine disulphonate (BCS), 
a copper chelator. Because ATP7B is able to move to LEs/lysosomes and PM 
in response to excess Cu (70), rescuing of Cu-dependent post-trafficking of 
the mutant was verified with ATP7B as positive control.  
The cells treated with BCS showed an evident Golgi localization of both 
ATP7B and mutant transporter in the presence of CRYAB peptide (Fig. 17). 
Interestingly, only in the presence of Pept1, ATP7B-H1069Q changed the 
subcellular localization from perinuclear compartments to post-Golgi vesicles 
in response to copper excess, similarly to ATP7B. Consequently, we 
observed an increase in ATP7B-H1069Q transfected cells exhibiting Golgi 
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staining in the BCS condition and vesicular staining after copper treatment 
(Fig. 17). 
In contrast, none of the described effects occurred with control peptide. 
 
 
 
Fig. 17. The Golgi-corrected ATP7B-H1069Q moves to post-Golgi 
vesicles in response to Cu overload in the presence of Pept1. COS-7 cells 
were transfected with GFP-tagged ATP7B or ATP7B-H1069Q and either co-
transfected with 3xFlag-CRYAB or CRYAB-R120G (data not shown) or 
incubated with Pept1 and Ctrl Pept (12.5 M) for 24 h post-transfection. Two 
days after transfection, cells were incubated for 2 h in a medium containing 
either 200μM CuSO4 (+Cu) or 500μM of the Cu chelant BCS 
(bathocuproinedisulfonic acid) (-Cu), and subsequently processed for 
confocal immunofluorescence analysis using an anti-GOLGA 2 protein 
antibody to visualize the Golgi complex. The white spots indicate a Golgi 
localization of ATP7B and ATP7B-H1069Q in the presence of Pept1 using 
low Cu conditions, whereas a punctate staining pattern of ATP7B and 
ATP7B-H1069Q with Pept1 is dispersed through the cytosolic vesicular 
compartment upon Cu exposure. Scale bar: 10 μm.  
The histogram shows the percentage of ATP7B or ATP7B-H1069Q 
transfected cells exhibiting ER, Golgi complex, ER + Golgi complex, and 
PM + vesicular staining (average ± s.d., n=25 cells from 2 independent 
experiments).  
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4.6 CRYAB peptide interacts with ATP7B-H1069Q 
 
To elucidate the mechanism of action of Pept1, we investigated whether it 
interacted with the WT and/or the mutated form of ATP7B through a FLIM-
FRET analysis and a co-immunoprecipitation (co-IP) assay followed by mass 
spectrometry (MS) analysis in COS-7 cells.  
In particular, fluorescence resonance energy transfer (FRET) microscopy is a 
technique used for quantifying the distance between two different 
fluorophores. It involves the transfer of energy from a fluorescent donor in its 
excited state to another excitable fluorophore. Therefore, FRET occurs when 
1) the distance between the donor and acceptor molecules is small (1-10 nm); 
2) the fluorescence emission spectrum of the donor molecule overlaps (to 
some extent) the excitation spectrum of the acceptor; 3) the donor emission 
decreases while the acceptor emission increases. (100). 
The principle of Fluorescence Lifetime Imaging Microscopy (FLIM) analysis 
is the same, except that it measures the donor fluorescence lifetime (rather 
than the intensity of fluorophore signal.  
The advantage of measuring fluorescence lifetime is that this parameter is 
directly dependent upon excited-state reactions but independent of 
fluorophore concentrations and the emission intensity through the sample, 
conditions difficult to take under control (101). 
A FRET phenomenon causes the reduction of donor lifetime due to the 
energy transfer toward the acceptor molecule (Fig. 18). Thus, when FLIM is 
measured in the presence of FRET, the donor lifetime reduction proves the 
putative interaction between two molecules. 
In our experimental plan, we transfected COS-7 cells with either GFP-
ATP7B or GFP-ATP7B-H1069Q (GFP was used as donor molecule) and 
treated them with 12.5 M of TAMRA-labelled Pept1 or control peptide for 
24 h (TAMRA was the acceptor fluorophore) (Fig. 18). FLIM-FRET analysis 
was performed in collaboration with Professor Sarnataro at CEINGE.  
For FLIM analysis, we used a random population of cells. We found that 
only in CRYAB-treated cells exhibiting a Golgi-like phenotype of the 
mutant, the donor fluorescence lifetime (GFP) decreased meaningfully (Fig. 
19). This result was emphasized by a 12% FRET efficiency value, calculated 
as percentage of the ratio between  of donor with acceptor and  of donor 
alone (Fig. 19). According to the literature data, this represents a significant 
value of FRET efficiency, suggesting a putative and preferential interaction 
between the CRYAB peptide and the mutated form of ATP7B. TAMRA-Ctrl 
Pept did not show a significant FRET signal, thereby providing evidence of a 
sequence-specific mechanism.  
We also performed co-immunoprecipitation in COS-7 cells treated as 
described above. After cellular lysis, the cells were incubated with a primary 
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antibody anti-GFP and then with Protein A-Sepharose beads. The 
immunoprecipitated samples were analysed through selected ion monitoring 
mass spectrometry (SIM-MS) in collaboration with Professor’s Scaloni group 
at ISPAAM (Michela Ciano Ph.D. thesis). This technique is particularly 
recommended when having to investigate the binding of small peptides given 
that it is highly sensitive for the detection and the identification of amino 
acids and peptides. The SIM-MS analysis confirmed the interaction between 
Pept1 and ATP7B-H1069Q, strongly supporting the FLIM-FRET data (data 
not shown). 
 
 
 
 
Fig. 18. Schematic representation of the principle of FLIM-FRET and 
fluorophores used in the experiment. The curve indicates the donor 
fluorescence lifetime (τ) that decreases when there is energy transfer towards 
the acceptor. 
 
 
Fig. 19. Pept 1 interacts with ATP7B-H1069Q. COS-7 cells were 
transfected with GFP-tagged ATP7B or ATP7B-H1069Q and incubated with 
TAMRA-labeled Pept1 and Ctrl Pept (12.5 M) for 24 h post-transfection. 
Then, cells were processed for FLIM analysis. The lifetimes of GFP-tagged 
ATP7B and ATP7B-H1069Q  alone or with TAMRA-labeled peptides are 
reported in the table on the right. 
On the left, the histograms show the percentage of FRET efficiency. A value 
of 12% strongly indicates that FRET occurs between Pept1-T and GFP-
ATP7B-H1069Q (average ± s.d., at least 10 cells from 3 independent 
experiments). 
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4.7 Differentiation toward hepatocytes of iPSCs obtained by 
reprogramming skin fibroblasts from a WD patient and his mother 
(control) 
 
All the studies discussed in the above sections were performed by 
overexpressing the mutant transporter in heterologous cells. However, we 
later realized that the only reliable strategy to study the molecular phenotype 
of the WD mutation and validate our in vitro results was to generate a new 
WD cellular system with the isogenic expression of the pathogenic mutant. 
To this aim, we used primary fibroblasts from skin biopsies of a WD patient 
carrying the H1069Q mutation (H1069Q/H1069Q) and his mother, as control 
(WT/H1069Q) (henceforth indicated as patient and control) to generate 
induced pluripotent stem cells (iPSCs) (Fig. 20).  
The generation, characterization, and hepatic differentiation of iPSCs was 
performed in collaboration with Doctor Silvia Parisi, Roman Polishchuk, 
Michela Ciano, and Anna Musto.  iPSCs were generated using an integration-
free method based on the transfection of episomal plasmids vectors into 
primary fibroblasts (96). Three weeks later, the iPSCs-like colonies were 
assessed for Nanog and Oct 4 stemness markers positivity by 
immunofluorescence (Fig. 21). After picking and expanding several clones 
from both samples, 2 WD iPSCs clones and 2 control iPSCs, which showed a 
normal karyotype, were grown under feeder-free conditions to avoid feeder 
contamination during differentiation. To ensure the maintenance of 
pluripotent stem cell markers, the expression of Oct 4 and Nanog was 
evaluated after multiple passages (≥15) through immunofluorescence 
microscopy and quantitative real-time RT-PCR (qPCR). 
For our purposes, we differentiated patient and control iPSCs into 
hepatocyte-like cells (HLCs) (Fig. 20) using a previously established protocol 
(97). This protocol comprises 3 hepatic developmental stages: definitive 
endoderm, hepatic progenitors and hepatocyte-like cells. The appearance of 
markers representative of each phase was assessed by immunofluorescence 
microscopy and qPCR. The cells were differentiated for 20 days, the time 
span required to result positive for hepatic cell markers: albumin (ALB) (data 
not shown), -fetoprotein (AFP), and 1-antitrypsin (AAT) (Fig. 21). 
Importantly, there were no differences between control and patient HLCs in 
the expression of differentiation markers, suggesting that the ATP7B 
mutation does not affect hepatic differentiation in our conditions. 
Finally, qPCR revealed a strong expression of ATP7B during hepatic 
differentiation; instead, immunofluorescence analysis showed that ATP7B 
positive population varied between 30 and 40% of the total cell population, 
similarly to control and patient HLCs (data not shown).  
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Thus, we advance the hypothesis that the generation of HCLs from control 
and patient iPSCs provides a powerful isogenic in vitro model to study 
ATP7B mutation. 
 
 
 
 
Fig. 20. Diagram of the main phases for the generation of a new isogenic 
WD cellular model. 
 
 
 
 
Fig. 21. Generation of iPSCs from human fibroblasts heterozygous and 
homozygous for the H1069Q mutation of ATP7B and characterization of 
HLCs obtained from iPSCs. Human fibroblasts from control (WT/H1069Q) 
and patient (H1069Q/H1069Q) were induced to reprogram; twenty-one days 
later, the presence of pluripotent stem cells colonies was assessed by 
immunofluorescence for stemness marker expression (Oct 4 and Nanog). The 
nuclei were stained with DAPI. Scale bars: 100 µm. 
The completion of hepatic differentiation was evaluated at 20 days by 
analyzing the presence of the functional hepatic marker AAT co-expressed 
with AFP. Scale bars: 50 µm. 
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4.8 ATP7B shows both a reticular and Golgi localization and is degraded 
faster  in patient HLCs than in control HLCs 
 
Subcellular distribution of ATP7B was investigated through confocal 
immunofluorescence analysis. After fixation, the cells were double-labeled 
with an antibody against ATP7B and with either Golgin 97 to recognize the 
Golgi complex or KDEL, used as an ER marker. 
In accordance with our experiments in heterologous and hepatic cell lines, we 
observed that in control HLCs ATP7B clearly colocolized with Golgin 97, 
indicating its Golgi localization.  
However, a single most striking result emerged from these experiments. In 
brief, whereas in previous work we demonstrated that ATP7B-H1069Q 
resides almost exclusively in the ER and that only a very small fraction is 
able to reach the Golgi compartment, here we observed that in patient HLCs, 
a significant fluorescence signal of the mutant was in the Golgi, whereas only 
moderate levels of ATP7B-H1069Q were detectable in the ER, possibly 
owing to the rapid degradation of the mutant (Fig. 22). 
Based on this result, we could speculate that, even though the mutation 
affects the trafficking of Cu transporter from the ER to Golgi, a significant 
part of the protein might nonetheless manage to pass the ER quality control 
checkpoints and reach the Golgi complex. 
In collaboration with Doctor Michela Ciano, Elena Polishchuk, and Roman 
Polishchuk, we tested this hypothesis by comparing overall ATP7B quantities 
in control and patient HLCs using Western Blot analysis. No ATP7B 
expression was detected in undifferentiated iPSCs of control and patient. By 
contrast, whereas it was strongly expressed in HLCs derived from control 
iPSCs,  the mutant was dimly  expressed in HLCs derived from patient iPSCs 
(Fig. 23A).  
Moreover, in the presence of cycloheximide (Chx), a protein synthesis 
inhibitor, a clear reduction in ATP7B-H1069Q level was observed after 4 h 
in patient HLCs, confirming the faster degradation of ATP7B-H1069Q 
compared to the WT protein (Fig. 23B). 
We also performed immunofluorescence analysis after treating cells with 
MG132, a reversible proteasome inhibitor that acts at the final step of the  
ER-associated degradation (ERAD) pathway. A clear reticular signal of 
ATP7B mutant was visible in patient HLCs exposed to MG132, suggesting 
that mutant degradation is due to ER retention (Fig. 23C). 
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Fig. 22. Intracellular localization of ATP7B in HLCs obtained from 
control and patient iPSCs. Confocal immunofluorescence analysis of HLCs 
immunolabeled for ATP7B and Golgin 97 (upper panels) or KDEL 
containing proteins (lower panels) as markers of Golgi complex and ER, 
respectively. White arrows point to Golgi complex containing ATP7B-
H1069Q in patient HLCs. Scale bars: 10 µm. 
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Fig. 23. Relative accumulation and degradation of ATP7B in HLCs 
obtained from control and patient iPSCs. (A) Western blot analysis of 
ATP7B accumulation at steady state in undifferentiated iPSCs and in the 
differentiated HLCs. Unrelated human iPSCs were used as further control. 
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The graph shows the relative expression of ATP7B in patient HLCs 
normalized to the level in the control HLCs. Data are reported as means ± 
SEM of 3 biological replicates. (B) Western blot analysis of ATP7B 
accumulation in control and patient HLCs incubated for 4 h in the absence or 
in the presence of 100 µM cycloheximide. The graph shows the relative 
expression of ATP7B at the 4 h time point normalized to the level of the 0 
time point. Data are reported as means ± SEM of 3 biological replicates. (C) 
Cells were treated with 30 μM MG132 for 6 h, then fix labeled with 
antibodies against ATP7B and ER resident protein BCAP31. Arrows indicate 
the ER, where ATP7B colocalizes with BCAP31 in patient hepatocyte-like 
cells. Scale bars: 6 µm. 
 
 
 
4.9 Golgi ATP7B pool responds to increasing copper levels in patient HLCs 
 
To better understand whether ATP7B-H1069Q retains its ability to 
redistribute to Cu excretion sites, we performed confocal 
immunofluorescence analysis after incubating cells with CuSO4 for 2 h. As 
expected, in control cells ATP7B was able to relocate towards post Golgi 
structures containing the LE/lysosome marker LAMP1 in response to 
increasing Cu levels. Intriguingly, in patient HLCs, the Golgi ATP7B pool 
showed a similar redistribution in the presence of copper overload (Fig. 24). 
This result suggests that ATP7B-H1069Q isogenically expressed in patient 
HLCs preserves its trafficking response to Cu overload, a finding that 
represents an important step towards the characterization of a mutant rescue 
strategy. 
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Fig. 24. Trafficking of ATP7B in response to high Cu level in HLCs 
obtained from control and patient iPSCs. Cells were treated with 200 M 
CuSO4 for 2 h and double-labeled with antibodies against ATP7B and 
LAMP1. Arrows indicate LAMP1-positive structures containing ATP7B both 
in control and patient hepatocyte-like cells exposed to Cu. Scale bars: 5.7 µm 
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5. CONCLUSIONS AND DISCUSSION 
 
Wilson Disease is a rare, inherited autosomal recessive disorder affecting 
1/7000 children worldwide (21). Prompt detection and early treatment are 
paramount to reverse its course. As of today, chelating agents and zinc 
therapy are considered the gold-standard treatments. The downside, however, 
is that despite being highly effective, they may give rise to serious adverse 
effects. Thus, the overall motivation of my research project was to identify 
new therapeutic prospects for the most frequent ATP7B mutation causing 
Wilson Disease. Extending on previous lines of research demonstrating that 
ATP7B-H1069 mutation retains residual Cu transport activity and that -
crystallin may very well play a pivotal role in correcting the mutant’s 
mislocalization to the ER, we set out to investigate the potential therapeutic 
implications of CRYAB-derived peptides in the treatment of WD. Moreover, 
to further corroborate our hypotheses and obtain more reliable results, we 
decided to step away from the more common heterologous or hepatoma-
derived cell lines and generated an isogenic WD cell line based on iPSCs 
from skin fibroblasts of a WD patient and his mother (control) and 
differentiated them into HLCs.  
Remarkably, some insightful findings emerged from my PhD project. First, 
we found that CRYAB-derived peptide (viz, 73-92) rescues the proper 
intracellular localization and Cu-dependent trafficking of ATP7B-H1069Q 
Indeed, we demonstrated for the first time the beneficial effects of a mini-
chaperone against the most frequent cause of Wilson disease in heterologous 
or hepatoma-derived cell lines overespressing the mutant protein.  
Second, we succeeded in generating a new isogenic WD cell model derived 
from iPSCs obtained by reprogramming fibroblasts from a patient and his 
mother, used as control. Thanks to the efficiency of this model, we were able 
to characterize for the first time the molecular dynamics of endogenously 
expressed ATP7B-H1069Q. The most important finding emerging under 
isogenic conditions was that loss of ATP7B function is mainly due to the 
rapid ER-associated degradation of the mutant, whereas only part of ATP7B-
H1069Q survives and localizes to the trans-Golgi compartment. Noteworthy, 
this result challenges the conventional view of ATP7B-H1069Q 
overexpression studies reporting that a massive accumulation of the mutant is 
caused by its inability to pass the ER control quality checkpoints.  
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Properties of CRYAB-derived peptide in cells overexpressing ATP7B-
H1069Q 
  
Wilson disease caused by ATP7B-H1069Q is thought to be caused by a 
partial misfolding of the protein. Consequently, stabilization of the native 
protein represents a logical therapeutic approach to ameliorate the 
pathological consequences (99). 
To reach this goal, cellular chaperones constitute the most obvious target. 
The rationale of targeting chaperones in conformational diseases is that 
modulating the expression level of the chaperone(s) most directly involved 
with a specific client protein might favorably induce homeostatic changes. 
Besides anti-aggregation properties, chaperones also participate in 
degradation and trafficking processes. Such pathways are closely intertwined  
with protein synthesis and folding, constituting the cellular proteostasis 
network (68, 69). Several studies have already demonstrated the 
multifunctional cellular properties of chaperones in diseases associated with 
protein  aggregation and apoptosis (93, 94). In particular, A- and B- 
crystallins have been studied extensively for their multiple functions in the 
lens where they are mainly expressed and in other tissues, and for their well 
recognized chaperone-like function (102).  
In a previous work, we demonstrated that the full-length CRYAB protein 
rescues the localization and trafficking of ATP7B-H1069Q in response to 
copper overload in transfected cells (70). This represented a very promising 
result to tackle the disease. However, the use of a full-length chaperone for 
therapeutic purposes has obvious limitations owing to the molecular size and 
specificity of action. Indeed, each chaperone has multiple sites of interaction 
with different client proteins (93), thus modulating its expression could 
translate into impairing the proteostasis network of the cell. To overcome 
these obstacles, we dissected the whole protein in its main domains. Our 
analysis clearly indicated that the -crystallin domain retains chaperone 
activity, whereas the N-terminal and C-terminal domains fail to mimic the 
effect of the parent protein in cells overexpressing the ATP7B mutant. This 
result fueled our interest in exploring the potential sequences in the crystallin 
domain of CRYAB able to retain a rescuing activity toward ATP7B-
H1069Q. In this context, studies in vitro have shown  that isolated peptides 
corresponding to residues 73-85 and 101-110 of the crystallin domain prevent 
fibril formation activity (91), whereas peptide 73-92 prevents aggregation 
and precipitation of denaturing alcohol dehydrogenase (92).  
The demonstration of chaperone-like activities in peptides derived from a 
smaller portion of the -crystallin domain clearly suggests the possibility of  
exploiting these mini-chaperones as a very effective therapeutic molecule 
(99). Indeed, unlike the parental protein, these peptides are smaller and more 
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amenable to manipulations for improvements in delivery, availability, target 
specificity, and molecular activities (79). Most relevant for these purposes is 
CRYAB-derived peptide 73-92. Recent studies have indeed demonstrated 
that this peptide exhibits anti-aggregation and anti-apoptotic effects in both 
cultured cells and experimental animals exposed to stress conditions (93, 94). 
Given its therapeutic potential, we have tested the synthetic CRYAB-derived 
peptide (73-92) in heterologous or hepatoma-derived cell lines 
overexpressing ATP7B-H1069Q to see if it was able to counteract Cu 
toxicity. For our purposes, we also used a form conjugated with TAMRA to 
track its intracellular localization.   
Remarkably, our experiments indicated that the peptide enters the cells and 
does not affect cell viability even after prolonged incubation periods. 
Although we still do not know how it actually penetrates into cells, our 
subcellular fractionation studies revealed that the peptide is mainly cytosolic 
and is only partially associated with lysosomes structures in a time-dependent 
fashion. Thus, the peptide exhibits important non toxicity properties and a 
cytosolic distribution most likely functional to its activity. 
The investigation of its role in the context of H1069Q mutation produced the 
most interesting results. First, we found that in the presence of the CRYAB 
peptide, ATP7B-H1069Q was rescued and correctly localized to the Golgi 
compartment. Moreover, the Golgi corrected ATP7B-H1069Q was also able 
to redistribute to post Golgi sites and, eventually, to the PM, in cells treated 
with the peptide and exposed to high Cu level.  
The ability of the peptide to rescue the Cu-dependent trafficking raised many 
questions about its mechanism of action. A first indication came from our 
FLIM-FRET and SIMS analysis. These analyses revealed that the CRYAB 
peptide interacts with the ATP7B copper transporter. Although many more 
questions remain unanswered, this finding does represent a first step towards 
understanding the mechanism of action against ATP7B-H1069Q mutant.   
Taken together these results open new promising avenues for correcting the 
the most frequent ATP7B mutation causing Wilson disease. Undoubtedly, an 
extensive biochemical and structural characterization of the peptide would 
provide a powerful instrument to identify the crucial residues and best 
possible modifications aimed at improving the activity of the peptide. In this 
context, CRYAB peptide could be used as a guide for high-throughput 
screenings to identify already druggable small molecules apt to correct the 
mislocalization of ATP7B-H1069Q. Finally, the study of its mechanism of 
action could expand our understanding of protein folding and open new 
therapeutic possibilities for Wilson disease and beyond. 
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New isogenic WD cell model and characterization of endogenously 
expressed ATP7B-H1069Q 
 
Validating disease-correcting strategies in cellular systems that would bear 
close similarities to patient-derived cells represents one of the most 
interesting therapeutic perspectives for protein-misfolding-mistrafficking 
diseases. Accordingly, one of the main research achievements in my PhD 
project has been the creation of a cellular model based on the differentiation 
of iPSCs into hepatocyte-like cells (HLCs). These cells were obtained by 
reprogramming skin fibroblasts of a homozygous (H1069Q/H1069Q) patient, 
and his mother, the latter used as control (WT/H1069Q). Thus, we obtained 
HLCs expressing the endogenous ATP7B forms at physiological level in the 
proper genetic background.  
In fact, previous studies have reported the generation of iPSCs from WD 
patients with R778L and M769V genetic mutations of ATP7B (103, 104). 
However, to our knowledge, we are the first research team to have generated 
human iPSCs from patients bearing the H1069Q ATP7B mutation. 
Moreover, two other aspects characterizing our cellular model are worthy of 
attention: 1) the use of episomal plasmids instead of retro- or lentivirus for 
reprogramming induction to avoid genetic integration in the patient’s cells; 2) 
the choice of a familiar control instead of human ESCs derived from human 
embryo of unrelated individuals, as described in other studies. 
From a future perspective, this model will offer scientists the opportunity to 
overcome the limitations of heterologous cellular systems that exhibit 
different genetic landscapes and proteostatic networks. One could argue that 
this obstacle could be circumvented by adopting a mammalian model. 
However, one drawback of using this system is that it could fail to 
recapitulate human disease because of genetic and epigenetic variability, 
thereby undermining drug validation screenings (105). Still another option 
could be the use of hepatocytes from liver biopsies. However, a disadvantage 
of this approach is the scant availability of cells from biopsies and their 
inability to proliferate in vitro (106). A more valid option for drug validation 
purpose could be the use of skin fibroblasts. Indeed, unlike other types of cell 
lines, they can be easily manipulated and expanded in vitro. In the context of 
ATP7B mutation, however, skin fibroblasts do not represent a valid 
alternative because they do not express ATP7B at a detectable level. 
All things considered, our HLC model system provides an excellent solution 
to test mutant-correcting strategies in WD and to overcome all the intrinsic 
limitations of other cellular models.  
Practically, HLCs offer several advantages. They are of human origin, have 
hepatocyte features, endogenously express the ATP7B-H1069Q mutant, and, 
finally, can be abundantly differentiated from iPSCs. Still another major 
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advantage is that iPSCs can also be differentiated into neurons. This 
additional property could enable researchers to study this mutation in the 
brain, considering that the H1069Q mutation of ATP7B is frequently 
associated with neurological aberration (107). Moreover, applying the recent 
CRISPR/Cas9 editing technology on patients’ iPSCs could generate 
WT/H1069Q, WT/WT, and null/null iPSCs a strategy that could throw more 
light on the complex dynamics of this mutant. 
The generation of this new WD cellular model has allowed us to study, for 
the first time, the molecular dynamics of ATP7B-H1069Q under isogenic 
conditions.  
The main finding emerging from our experiments is that loss of ATP7B 
function is mainly due to a higher degradation of the misfolded protein.  
Another surprising finding of my research is that a significant pool of the 
mutant protein is present in the Golgi compartment, a finding that challenges 
previous studies reporting a strong accumulation of ATP7B-H1069Q in the 
ER. Moreover, the overall amount of ATP7B protein in patient HLCs was 3 
times lower than that in control cells, although ATP7B mRNA levels were 
similar. Taken together these results suggest that although most of the newly-
synthesized mutant undergoes rapid degradation, a small part of ATP7B-
H1069Q survives, thereby reaching the Golgi destination.  
In this regard, we have also demonstrated that the rapid degradation of the 
mutant takes place in the ER. Indeed, the suppression of proteasomal 
degradation strongly increases ATP7B mutant signal in the ER of patient 
HLCs. We also observed that the fraction of the mutant in the TGN is able to 
move to LEs/lysosomes structures in response to increased levels of Cu, as 
efficiently as the WT transporter. This is in line with the results obtained in 
the presence of CRYAB peptide. Unfortunately, this Cu-dependent 
trafficking response is not sufficient to prevent the disease because of the 
decreased expression of ATP7B-H1069Q. Therefore, new therapeutic 
research aimed at increasing the number of molecules reaching the TGN is 
highly warranted.   
In contrast, the results of our studies as well as those of others, performed by 
overexpressing ATP7B-H1069Q in heterologous or hepatoma-derived cell 
lines, have indicated that ATP7B-H1069Q is massively trapped in the ER, 
exhibiting a severely impaired trafficking capability to Golgi and 
ER/lysosome structures in response to Cu overload (45, 58, 59, 70, 108). 
Regardless of such ER retention, the mutant conserves a significant residual 
Cu transport activity tantamount to 20 to 70% of WT ATP7B protein (59, 
61). Such evidence has led to the conclusion that treatments that facilitate the 
sorting of the mutant from the ER into the secretory pathway would represent 
a major therapeutic approach. However, evidence that ATP7B-H1069Q 
undergoes an accelerated ER-associated degradation would also seem to 
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suggest that using inhibitors to reduce the mutant’s rapid degradation could 
be a crucially valid alternative to counter WD-associated ATP7B-H1069Q 
mutant. 
Unquestionably, the major findings emerging from my research project do 
warrant further investigation. Accordingly, future studies will need (1) to 
further optimize our new isogenic model system, for instance, by increasing 
the population of HLCs obtained after iPSCs differentiation, (2) they will 
need to validate the rescuing activity of CRYAB peptide, and (3) they will 
need to test the safety and efficiency of other correcting agents for this 
common form of WD. However, I am adamantly hopeful that my research 
team, also thanks to the fruitful collaboration with other research labs, has 
laid the groundwork for future efforts in this arduous but promising line of 
research.
                                                                                                                 6. Acknowledgements  
 
57 
 
6. ACKNOWLEDGEMENTS 
 
This work was supported by Telethon grant n. GGP 14002 to S.B. I wish to 
thank Prof. Massimo Mallardo and Dr. Maria Gabriella Caporaso for their 
technical help and useful advices and Dr. Paola Merolla for editing the final 
draft of my thesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                               7. References 
 
58 
 
7. REFERENCES 
      
1) de Bie P, Muller P, Wijmenga C, Klom LWJ. Molecular 
pathogenesis of Wilson and Menkes disease: correlation of mutations 
with molecular defects and disease phenotypes. J Med Genet 2007; 
44:673-688.  
 
2) Lutsenko S, Barnes NL, Bartee MY, Dmitriev OY. Function and 
Regulation of Human Copper-Transporting ATPases. Physiol Rev 
2007; 87:1011-1046. 
 
3) Bissig K D, Honer M, Zimmermann K, Summer K H, Solioz M. 
Whole animal copper flux assessed by positron emission tomography 
in the Long-Evans cinnamon rat-a feasibility study. Biometals 2005; 
18:83-88. 
 
4) Linder MC, Moriya M, Whon A, Kassa A, Gilley C. Vesicular 
transport of Fe and interaction with other metal ions in polarized 
Caco2 cell monolayers. Biol Res 2006; 39:143-156. 
 
5) Culotta VC, Yang M, O’Halloran TV. Activation of superoxide 
dismutases: putting the metal to the pedal. Biochim Biophys Acta 
2006; 1763:747-758. 
 
6) Horng YC, Cobine PA, Maxfield AB, Carr HS, Winge DR. 
Specific copper transfer from the Cox17 metallochaperone to both 
Sco1 and Cox11 in the assembly of yeast cytochrome c oxidase. 
J Biol Chem 2004; 279:35334-35340. 
 
7) Prohaska JR, Gybina AA. Intracellular copper transport in 
mammals. J Nutr 2004; 134:1003-1006. 
 
8) Punter FA, Glerum DM. Mutagenesis reveals a specific role for 
Cox17p in copper transport to cytochrome oxidase. J Biol Chem 
2003; 278:30875-30880. 
 
9) Hamza I, Faisst A, Prohaska J, Chen J, Gruss P, Gitlin JD. The 
metallochaperone Atox1 plays a critical role in perinatal copper 
homeostasis. Proc Natl Acad Sci USA 2001; 98:6848-6852. 
 
                                                                                                                               7. References 
 
59 
 
10) Hamza I, Prohaska J, Gitlin JD. Essential role for Atox1 in the   
copper-mediated intracellular trafficking of the Menkes ATPase. 
Proc Natl Acad Sci USA 2003; 100:1215-1220. 
 
11) Walker JM, Tsivkovskii R, Lutsenko S. Metallochaperone  
Atox1transfers copper to the NH2-terminal domain of the Wilson’s 
disease protein and regulates its catalytic activity. J Biol Chem 2002; 
277:27953-27959. 
 
12) Menkes JH, Alter M, Steigleder GK, Weakley DR, Sung JH. A 
sex-linked recessive disorder with retardation of growth, peculiar 
hair, and focal cerebral and cerebellar degeneration. Pediatrics 1962; 
29:764-79. 
 
13) Danks DM, Campbell PE, Walker-Smith J, Stevens BJ, Gillespie 
JM, Blomfield J, Turner B. Menkes’ kinky-hair syndrome. Lancet 
1972; 1:1100-2. 
 
14) Tonnesen T, Kleijer WJ, Horn N. Incidence of Menkes disease. 
Hum Genet 1991; 86:408-10. 
 
15) Gu YH, Kodama H, Shiga K, Nakata S, Yanagawa Y, Ozawa H. 
A survey of Japanese patients with Menkes disease from 1990 to 
2003: incidence and early signs before typical symptomatic onset, 
pointing the way to earlier diagnosis. J Inherit Metab Dis 2005; 
28:473-8. 
 
16) Danks DM. Disorders of Copper transport. In: Scriver CR, 
Beaudet AL, Sly WM, et al, eds. The metabolic and molecular 
basis of inherited disease. New York: McGraw-Hill 1995; 2211-35. 
 
17) Kaler SG. Diagnosis and therapy of Menkes syndrome, a genetic 
form of copper deficiency. Am J Clin Nutr 1998; 67:1029S-1034S. 
 
18) Kodama H, Murata Y. Molecular genetics and pathophysiology of 
Menkes disease. Pediatr Int 1999; 41:430-435. 
 
19) Kodama H, Murata Y, Kobayashi M. Clinical manifestations and 
treatment of Menkes disease and its variants. Pediatr Int 1999;  
41:423-429. 
 
 
                                                                                                                               7. References 
 
60 
 
20) Fei W, Jing W, Chunwen P, Liang Q, and Chunmeng J. Wilson’s 
Disease: A Comprehensive Review of the Molecular Mechanisms. 
Int J Mol Sci 2015; 16, 6419-6431. 
 
21) Coffey AJ, Durkie M, Hague S, McLay K, Emmerson J, Lo C, 
Klaffke S, et al. A genetic study of Wilson's disease in the United 
Kingdom. Brain 2013; 136:1476-1487. 
 
22) Seniow J, Mroziak B, Czlonkowska A, Jedryka-Goral A. Self-
rated emotional functioning of patients with neurological or 
asymptomatic form of Wilson’s disease. J Clin Neuropsychol 2004; 
17, 367-373. 
 
23) Zimbrean PC, Schilsky ML. Psychiatric aspects of Wilson disease: 
A review. Gen Hosp Psychiatry 2014; 36, 53-62. 
 
24) Roberts EA, Schilsky ML. A practice guideline on Wilson disease. 
Hepatology 2003; 37,1475-1492. 
 
25) Beinhardt S, Leiss W, Stattermayer AF, Graziadei I, Zoller H, 
Stauber R, Maieron A, Datz C, Steindl-Munda P, Hofer H, et al. 
Long-term outcomes of patients with Wilson disease in a large 
Austrian cohort. Clin Gastroenterol Hapatol 2014; 12, 683-689. 
 
26) Scheinberg IH, Gitlin D. Deficiency of ceruloplasmin in patients 
with hepatolenticular degeneration (Wilson’s disease). Science 
1952; 116:484-5. 
 
27) Riordan SM, Williams R. The Wilson’s disease gene and 
phenotypic diversity. J Hepatol 2001; 34:165-71. 
 
28) Dong QY, Wu ZY. Advance in the pathogenesis and treatment of 
Wilson disease. Transl Neurodegener  2012; 9158-1-23. 
 
29) Kenny S, Cox DW. Wilson disease mutation database. 
http://www.medicalgenetics.med.ualberta.ca/wilson/index.php. 
 
30) Hsi G, Cox DW. A comparison of the mutation spectra of Menkes 
disease and Wilson disease. Hum Genet 2004; 114:165-72. 
 
                                                                                                                               7. References 
 
61 
 
31) Ferenci P. Regional distribution of mutations of the ATP7B gene in   
patients with Wilson disease: impact on genetic testing. Hum Genet 
2006; 120:151-9. 
 
32) Walshe JM. Wilson’s disease; new oral therapy. Lancet 1956; 
270:25-6. 
 
33) Tanzi RE, Petrukhin K, Chernov I, Pellequer JL, Wasco W, 
Ross B, Romano DM, Pavone L, Brzustowicz LM. The Wilson 
disease gene is a copper transporting ATPase with homology to the 
Menkes disease gene. J Nat Genet 1993; 5, 344-350. 
 
34) Lutsenko S, Efremov RG, Tsivkovski R, Walker JM. Human   
copper-transporting ATPase ATP7B (the Wilson’s disease protein): 
Biochemical properties and regulation. J Bioenerg Biomembr 2002; 
34, 351-362. 
 
35) Myari A, Hadjiliadis N, Fatemi N, Sarkar B. Copper (I) 
interaction with model peptides of WD6 and TM6 domains of 
Wilson ATPase: Regulatory and mechanistic implications. J Inorg 
Biochem 2004; 98, 1483-1494. 
 
36) Fatemi N, Sarkar B. Molecular mechanism of copper transport in 
Wilson disease. Environ Health Perspect 2002; 110, 695-698. 
 
37) Huster D, Lusenko S. The distinct roles of the N-terminal copper-
binding sites in regulation of catalytic activity of the Wilson’s 
disease protein. J Biol Chem  2003; 278, 32212-32218. 
 
38) Cater MA, La Fontaine S, Mercer JFB. Copper binding to the N-
terminal metal-binding sites or the CPC motif is not essential for 
copper-induced trafficking of the human Wilson protein 
(ATP7B). Biochem J 2007; 401, 143-153. 
 
39) Tsivkovskii R, MacArthur BC, Lutsenko S. The Lys1010-
Lys1325 fragment of the Wilson’s disease protein binds nucleotides 
and interacts with the N-terminal domain of this protein in a copper-
dependent manner. J Biol Chem 2001; 19, 2334-2342. 
 
 
 
                                                                                                                               7. References 
 
62 
 
40) Dmitriev O, Tsivkoskii R, Abildgaard F, Morgan CT, Markley 
HL, Lutsenko S. Solution structure of the N-domain of Wilson 
disease protein: Distinct nucleotide-binding environment and effects 
of disease mutations. Proc Natl Acad Sci USA 2006; 103, 5302-
5307. 
 
41) Sazinsky MH, Mandal AK, Arguello JM, Rosenzweig AC. 
Structure of the ATP bind domain from the Archaeoglobus fulgidus 
Cu+-ATPase. J Biol Chem 2006; 281, 11161-11166. 
 
42) Miller JV, Juul B, Maire M. Structural organization, ion transport, 
and energy transduction of P-type ATPases. Biochim Biophys Acta 
1996; 1286, 1-51. 
 
43) Moller LB, Ott P, Lund C, Horn N. Homozygosity for a gross 
partial gene deletion of the C-terminal end of ATP7B in a Wilson 
patient with hepatic and no neurological manifestations. Am J Med 
Genet 2005; 138, 340-343. 
 
44) Braiterman L, Nyasae L, Leves F, Hubbard AL. Critical roles for 
the COOH terminus of the Cu-ATPase ATP7B in protein stability, 
trans-Golgi network retention, copper sensing, and retrograde 
trafficking. Am J Physiol Gastrointest Liver Physiol 2011; 301: 
G69-G81. 
   
45) Huster D, Hoppert M, Lutsenko S, Zinke J, Lehmann C, 
Mossner J, Berr F, Caca K. Defective cellular localization of 
mutant ATP7B in Wilson’s disease patients and hepatoma cell lines. 
Gastroenterology 2003; 124, 335-345. 
 
 
46) Lutsenko S, Tsivkovskii R, Walker JM. Functional properties of 
the human copper-transporting ATPase ATP7B (the Wilson’s 
disease protein) and regulation by metallochaperone Atox1. 
Ann N Y Acad Sci 2003; 986, 204-211. 
 
47) Harada M, Kawaguchi T, Kumemura H, Terada K, Ninomiya 
H, Taniquchi E, Hanada S, Maeyama M, Koqa H, Ueno T, et al. 
The Wilson disease protein ATP7B resides in the late endosomes 
with Rab7 and the Niemann-Pick C1 protein. Am J Pathol 2005; 
166, 499-510. 
 
                                                                                                                               7. References 
 
63 
 
48) Gitlin JD. Copper homeostasis: Specialized functions of the late 
secretory pathway. Dev Cell 2014; 29, 631-632. 
 
49) Polishchuk EV, Concilli M, Iacobacci S, Chesi G, Pastore N, 
Piccolo P, Paladino S, Baldantoni D, van IJzendoorn SC, Chan 
J, et al. Wilson disease protein ATP7B utilized lysosomal 
exocytosis to maintain copper homeostasis. Dev Cell 2014; 29, 686-
700. 
 
50) Cater M, la Fontaine S, Shield K, Deal Y, Mercer FBJ. ATP7B 
mediates vesicular sequestration of copper; Insight into biliary 
copper excretion. Gastroenterology 2006; 130, 493-506. 
 
51) Kucinskas L, Jeroch J, Vitkauskiene A, Sakalauskas R, 
Petrenkiene V, Kucinskas V, Naginiene R, Schmidt H, 
Kupcinskas L. High frequency of the c.3207C>A (p.H1069Q) 
mutation in ATP7B gene of Lithuanian patients with hepatic 
presentation of Wilson’s disease. World J Gastroenterol 2008; 14, 
5876-5879. 
 
52) Gromadzka G, Schmidt HH, Genschel J, Bochow B, Rodo M, 
Tarnacka B, Litwin T, Chabik G, Czonkowska A. Frameshift and 
nonsense mutations in the gene for ATPase are associated with sever 
impairment of copper metabolism and with an early clinical 
manifestation of Wilson’s disease. Clin Genet 2005; 68, 524-532. 
 
53) Cox DW, Fraser FC, Sass-Kortsak A. A genetic study of Wilson’s 
disease: Evidence for heterogeneity. Am J Hum Genet 1972; 24, 
646-666. 
 
54) Lepori MB, Zappu A, Incollu S, Dessi V, Mameli E, Demelia L, 
Nurchi AM, Gheorghe L, Maggiore G, Sciveres M, et al. 
Mutation analysis of the ATP7B gene in a new group of Wilson’s 
disease patients: Contribution to diagnosis. Mol Cell Probes 2012; 
26, 147-150. 
 
55) Roberts EA, Schilky ML. Diagnosis and treatment of Wilson 
disease: An update. Hepatology 2008; 47, 2089-2111. 
 
 
 
                                                                                                                               7. References 
 
64 
 
56) Usta J, Daya HA, Halawi H, Al-Shareef I, EI-Rifai O, Malli AH, 
Sharara AI, Habib RH, Barada K. Homozygosity for non-
H1069Q missense mutation in ATP7B gene and early severe liver 
disease: Report of two families and a meta-analysis. JIMD Rep 
2012; 4, 129-137. 
 
57) La Fontaine S, Mercer JFB. Trafficking of the copper-ATPOases 
ATP7A and ATP7B: role in copper homeostasis. Arch Biochem 
Biophys 2007; 463:149-167. 
 
58) Payne AS, Kelly EJ, Gitlin JD. Functional expression of the 
Wilson disease protein reveals mislocalization and impaired copper-
dependent trafficking of the common H1069Q mutation. Proc Natl 
Acad Sci U S A 1998; 95:10854-10859. 
 
59) van den Berghe PV, Stapelbroek JM, Krieger E, de Bie P, van 
de Graaf SF, de Groot RE, van Beurden E, Spijker E, Houwen 
RH, Berger R, Klomp LW. Reduced expression of ATP7B 
affected by Wilson disease-causing mutations is rescued by 
pharmacological folding chaperones 4-phenylbutyrate and curcumin. 
Hepatology 2009; 50(6):1783-95.  
 
60) Huster D, Kühne A, Bhattacharjee A, Raines L, Jantsch V, Noe 
J, Schirrmeister W, Sommerer I, Sabri O, Berr F, Mössner J, 
Stieger B, Caca K, Lutsenko S. Diverse functional properties of 
Wilson disease ATP7B variants. Gastroenterology 2012; 
142(4):947-956.e5. 
 
61) Chandhok G, Horvath J, Aggarwal A, Bhatt M, Zibert A, 
Schmidt HH. Functional analysis and drug response to zinc and D-
penicillamine in stable ATP7B mutant hepatic cell lines. World J 
Gastroenterol 2016; 22(16):4109-1919. 
 
62) Dmitriev OY, Bhattacharjee A, Nokhrin S, Uhlemann E-ME, 
Lutsenko S. Difference in stability of the N-domain underlies 
distinct intracellular properties of the E1064A and H1069Q mutants 
of copper-transporting protein ATPase ATP7B. J Biol Chem 2011; 
286:16355-16362. 
 
 
 
                                                                                                                               7. References 
 
65 
 
63) Banci L, Bertini I, Cantini F, Rosenzweig A, Yatsunyk LA. 
Metal binding domains 3 and 4 of the Wilson disease protein: 
Solution structure and interaction with the copper(I) chaperone 
HAH1. Biochemistry 2008; 47:7423-7429. 
 
64) Gitlin JD. Wilson disease. Gastroenterology 2003; 125:1868-1877. 
 
65) Braakman I, Bulleid NJ. Protein folding and modification in the 
mammalian endoplasmic reticulum. Annu Rev Biochem 2011; 
80:71-99. 
 
66) Mayer MP, Bukau B. Hsp70 chaperones: cellular functions and 
molecular mechanism. Cell Mol Life Sci 2005; 62:670-684. 
 
67) Pearl LH, Prodromo C. Structure and mechanism of the Hsp90 
molecular chaperone machinery. Annu Rev Biochem 2006; 75:271-
294. 
 
68) Ong DS, Kelly JW. Chemical and/or biological therapeutic 
strategies to ameliorate protein misfolding diseases. Curr Opin Cell 
Biol 2010; 23:231-238. 
 
69) Roth DM, Balch WE. Modeling general proteostasis: proteome 
balance in health and disease. Curr Opin Cell Biol 2010; 23:126-
134. 
 
70) D'Agostino M, Lemma V, Chesi G, Stornaiuolo M, Cannata 
Serio M, D'Ambrosio C, Scaloni A, Polishchuk R, Bonatti S. The 
cytosolic chaperone a-Crystallin B rescues appropriate folding and 
compartmentalization of misfolded multispan transmembrane 
proteins. J Cell Sci 2013; 126:4160-4172. 
 
71) Kappe G, Franck E, Verschuure P, Boelens WC, Leunissen JA, 
de Jong WW. The human genome encodes 10 alpha-crystallin-
related small heat shock proteins: HspB1-10. Cell Stress Chaperones 
2003; 8:53-61. 
 
72) Slingsby C, Wistow GJ, Clark AR. Evolution of crystallins for a 
role in the vertebrate eye lens. Protein Sci  2013; 22:367-380. 
 
 
                                                                                                                               7. References 
 
66 
 
73) Santhoshkumar P, Murugesan R, Sharma KK. Deletion of 
(54)FLRAPSWF(61) residues decreases the oligomeric size and 
enhances the chaperone function of alphaB-crystallin. Biochemistry  
2009; 48:5066-5073. 
 
74) Srinivas PN, Reddy PY, Reddy GB. Significance of alpha-
crystallin heteropolymer with a 3:1 alphaA/alphaB ratio: chaperone-
like activity, structure and hydrophobicity.  
 
Biochem J  2008; 414:453-460. 
 
75) Dubin RA, Wawrousek EF, Piatigorsky J. Expression of the 
murine alpha Bcrystallin gene is not restricted to the lens. Mol Cell 
Biol 1989; 9:1083-1091. 
 
76) Deretic D, Aebersold RH, Morrison HD, Papermaster DS. Alpha 
A- and alpha Bcrystallin in the retina. Association with the post-
Golgi compartment of frog retinal photoreceptors. J Biol Chem  
1994; 269:16853-16861. 
 
77) Iwaki T, Kume-Iwaki A, Goldman JE. Cellular distribution of 
alpha B-crystallin in non-lenticular tissues. J Histochem Cytochem  
1990; 38:31-39. 
 
78) Bhat SP, Nagineni CN. Alpha B subunit of lens-specific protein 
alpha-crystallin is present in other ocular and non-ocular tissues. 
Biochem Biophys Res Commun 1989; 158:319-325. 
 
79) Nagaraj RH, Nahomi RB, Mueller NH, Raghavan CT, Ammar 
DA, Petrash JM. Therapeutic potential of α-crystallin. Biochim 
Biophys Acta 2015; 1860:252-7. 
 
80) Liu JP, Schlosser R, Ma WY, Dong Z, Feng H, Liu L, Huang 
XQ, Liu Y, Li DW. Human alphaA- and alphaB-crystallins prevent 
UVA-induced apoptosis through regulation of PKCalpha, 
RAF/MEK/ERK and AKT signaling pathways. Exp Eye Res 
2004; 79:393-403. 
 
81) Xu F, Yu H, Liu J, Cheng L. alphaB-crystallin regulates oxidative 
stress-induced apoptosis in cardiac H9c2 cells via the PI3K/AKT 
pathway. Mol Biol Rep 2013; 40:2517-2526. 
 
                                                                                                                               7. References 
 
67 
 
82) Sreekumar PG, Kannan R, Kitamura M, Spee C, Barron E, 
Ryan SJ, Hinton DR. aB crystallin is apically secreted within 
exosomes by polarized human retinal pigment epithelium and 
provides neuroprotection to adjacent cells. PLoS One 2010; 
5:e12578. 
 
83) Treweek TM, Rekas A, Lindner RA, Walker MJ, Aquilina JA,  
Robinson CV, Horwitz J, Perng MD, Quinlan RA, Carver JA. 
R120G alphaB-crystallin promotes the unfolding of reduced alpha-
lactalbumin and is inherently unstable. Febs J  2005; 272:711-24. 
 
84) Garrido C, Kampinga HH, eds. Small HSPs in physiology and 
pathology. Int J Biochem cell Biol 2012; 44(10):1587-1710. 
 
85) Bakthisaran R, Akula KK, Tangirala R, Rao Ch M. 
Phosphorylation of alphaBcrystallin: role in stress, aging and patho-
physiological conditions. Biochim Biophys Acta 2016; 1860:167-82. 
 
86) Smith JB, Sun Y, Smith DL, Green B. Identification of the 
posttranslational modifications of bovine lens alpha B-crystallins by 
mass spectrometry. Protein Sci 1992; 1:601-8. 
 
87) Ahmad MF, Raman B, Ramakrishna T, Rao Ch M. Effect of 
phosphorylation on alpha B-crystallin: differences in stability, 
subunit exchange and chaperone activity of homo and mixed 
oligomers of alpha B-crystallin and its phosphorylation-mimicking 
mutant. J Mol Biol 2008; 375:1040-51. 
 
88) Ciano M, Allocca S, Ciardulli MC, della Volpe L, Bonatti S,  
D’Agostino M. Differential phosphorylation-based regulation of 
aBcrystallin chaperone activity for multipass transmembrane 
proteins. Biochem and Biophys Res Com 2016; 479(2):325-330. 
 
89) Robitaille J, MacDonald ML, Kaykas A, Sheldahl LC, Zeisler J, 
Dube MP, Zhang LH, Singaraja RR, Guernsey DL, Zheng B, 
Siebert LF, Hoskin-Mott A, Trese MT, Pimstone SN, Shastry 
BS, Moon RT, Hayden MR, Goldberg YP, Samuels ME. Mutant 
frizzled-4 disrupts retinal angiogenesis in familial exudative 
vitreoretinopathy. Nat Genet 2002; 32:326-30. 
 
 
 
                                                                                                                               7. References 
 
68 
 
90) Ecroyd H, Meehan S, Horwitz J, Aquilina JA, Benesch JL, 
Robinson CV, Macphee CE, Carver JA. Mimicking 
phosphorylation of alphaB-crystallin affects its chaperone activity. 
Biochem J  2007; 401:129-41. 
 
91) Ghosh JG, Houck SA, Clark JI. Interactive sequences in the 
molecular chaperone, human aB crystalline modulate the fibrillation 
of amyloidogenic proteins. Int J Biochem cell Biol 2008; 40:954- 
967. 
 
92) Bhattacharyya J, Padmanabha U, Wang J, Sharma KK. Mini-
aB-crystallin: a functional element of aB crystalline with chaperone-
like activity. Biochemistry 2006; 7:3069-3076. 
 
93) Sreekumar PG, Chothe P, Sharma KK, Baid R, Kompella U, 
Spee C, Kannan N, Manh C, Ryan SJ, Ganapathy V, Kannan R, 
Hinton DR. Antiapoptotic Properties of a-Crystallin-Derived 
Peptide Chaperones and Characterization of Their Uptake 
Transporters in Human RPE Cells. Invest Ophthalmol Vis Sci 2013; 
54:2787-2798. 
 
94) Nahomi RB, Wang B, Raghavan CT, Voss O, Doseff AI, 
Santhoshkumar P, Nagaraj RH. Chaperone Peptides of a-
Crystallin Inhibit Epithelial Cell Apoptosis, Protein Insolubilization, 
and Opacification in Experimental Cataracts. J Biol Chem 2013; 
288:13022-13035. 
 
95) Chandhok G, Schmitt N, Sauer V, Aggarwal A, Bhatt 
M, Schmidt HH. The effect of zinc and D-penicillamine in a stable 
human hepatoma ATP7B knockout cell line. PLoS One 2014; 
9(6):e98809. 
 
96) Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, 
Okamoto S, Hong H, Nakagawa M, Tanabe K, Tezuka K, 
Shibata T, Kunisada T, Takahashi M, Takahashi J, Saji H, 
Yamanaka S. A more efficient method to generate integration-free 
human iPS cells. Nat Methods 2011; 8(5):409-12. 
 
97) Si-Tayeb K, Noto FK, Nagaoka M, Li J, Battle MA, Duris C, 
North PE, Dalton S, Duncan SA. Highly efficient generation of 
human hepatocyte-like cells from induced pluripotent stem cells. 
Hepatology 2010; 51(1):297-305. 
                                                                                                                               7. References 
 
69 
 
 
98) Asomugha CO, Gupta R, Srivastava OP. Structural and functional 
roles of deamidation of N146 and/or truncation of NH2- or COOH-
termini in human B-crystallin. Mol Vis 2011; 17:2407-2420. 
 
99) Raju M, Santhoshkumar P, Sharma KK. Alpha-crystallin-derived 
peptides as therapeutic chaperones. Biochim Biophys Acta 2015; 
1860(1 Pt B):246-51.  
 
100) Gordon GW, Berry G, Liang XH, Levine B, Herman B. 
Quantitative fluorescence resonance energy transfer measurements 
using fluorescence microscopy. Biophys J 1998; 74(5):2702-13. 
 
101) Leavesley SJ, Rich TC. Overcoming limitations of FRET 
measurements. Cytometry A 2016; 89, 325-7. 
 
102) Kannan R, Sreekumar PG, Hinton DR. Novel roles for -
crystallins in retinal function and disease. Prog Retin Eye Res. 
2012; 31:576-604. 
 
103) Zhang S, Chen S, Li W, Guo X, Zhao P, Xu J, Chen Y, Pan 
Q, Liu X, Zychlinski D, Lu H, Tortorella MD, Schambach 
A, Wang Y, Pei D, Esteban MA. Rescue of ATP7B function in 
hepatocyte-like cells from Wilson's disease induced pluripotent stem 
cells using gene therapy or the chaperone drug curcumin. 
Hum Mol Genet 2011; 20(16):3176-87. 
 
104) Yi F, Qu J, Li M, Suzuki K, Kim NY, Liu GH, Belmonte JC. 
Establishment of hepatic and neural differentiation platforms 
of Wilson's disease specific induced pluripotent stem cells. Protein 
Cell 2012; 3(11):855-63. 
 
105) Jucker M. The benefits and limitations of animal models for 
translational research in neurodegenerative diseases. Nat Med 2010; 
16(11):1210-4.  
 
106) Huch M, Koo BK. Modeling mouse and human development using 
organoid cultures. Development 2015; 142(18):3113-25. 
 
 
 
                                                                                                                               7. References 
 
70 
 
107) Stapelbroek JM, Bollen CW, van Amstel JK, van Erpecum KJ, 
van Hattum J, van den Berg LH, Klomp LW, Houwen RH. The 
H1069Q mutation in ATP7B is associated with late and neurologic 
presentation in Wilson disease: results of a meta-analysis. J 
Hepatol 2004; 41(5):758-63. 
 
108) Chesi G, Hegde RN, Iacobacci S, Concilli M, Parashuraman S, 
Festa BP, Polishchuk EV, Di Tullio G, Carissimo A, Montefusco 
S, Canetti D, Monti M, Amoresano A, Pucci P, van de Sluis B, 
Lutsenko S, Luini A, Polishchuk RS. Identification of p38 MAPK 
and JNK as new targets for correction of Wilson disease-causing 
ATP7B mutants. Hepatology 2016; 63(6):1842-59. 
 
                                                                                                                8. List of publications 
 
71 
 
8. LIST OF PUBLICATIONS 
 
 Ciano M*, Allocca S*, Ciardulli MC, della Volpe L, Bonatti S, 
D’Agostino M. Differential phosphorylation-based regulation of 
aBcrystallin chaperone activity for multipass transmembrane proteins. 
Biochemical and Biophysical Research Communications. 479(2): 
325-330. 2016 October 14. PMCID: PMC505354. 
* These authors contributed equally to this work 
 
 MANUSCRIPT SUBMITTED 
Parisi S, Polishchuk EV, Allocca S, Ciano M, Musto A, Gallo M, 
Perone L, Ranucci G, Iorio R, Polishchuk RS, Bonatti S. 
Characterization of the most frequent ATP7B mutation causing 
Wilson disease in hepatocytes derived from patient induced 
pluripotent stem cells.  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
